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REBECCA SUE BOEHM. On the utility of stochastic models of chronic obstructive pulmonary 
dig~se. (Under the direction of ROBERT WOOLSON). 
Cbronic obstructive pulmonary disease (COPD) is a progressive and irreversible lung disease char-
I &cterized by reduced lung function, abnormal inflammatory response, dyspnea, increased sputum 
production, and costly and debilitating exacerbations. Common treatments for COPD include 
smoking cessation therapy, short- and long-acting bronchodilators, inhaled corticosteroids, pul-
monary rehabilitation, and home oxygen therapy. However, a recent rneta-analysis demonstrated 
that inhaled corticosteroids fail to slow the decline in FEV 1, the primary clinical marker of COPD 
progression. In addition, some evidence exists to suggest that long-term inhaled corticosteroid use 
rnay increase bone density loss, leading to osteoporosis. Given that the bone health effects of inhaled 
corticosteroid usc may have detrimental effects on patient health-related quality of life and increase 
direct medical costs, while having no effect on the primary clinical marker of disease progression, 
the wisdom of their widespread use among COPD sufferers has beconle a topic of hot debate in 
the pulmonary community. We addressed the common clinical questions surrounding the efficacy 
and side effects of inhaled corticosteroids through the application of two literature-based Markov 
models of direct medical costs and patient quality of life over short and long simulation periods. 
The three-year model of disease progression and exacerbations indicates that inhaled corticosteroid 
use is a cost-saving measure of improving patient quality of life, with cost-savings ranging frorTI 
$7,500 to $150,000 per quality-adjusted life year gained. The use of inhaled corticosteroids also 
reduces the fraction of severe exacerbations; however, it appears that their use does not slow pro-
gression to more severe forms of COPD. The twenty-year model of osteoporotic fractures in COPD 
patients demonstrates that, in the worst case, the use of inhaled corticosteroids simultaneously 
fails to increase patient mortality or decrease the number of quality-adjusted life years lived by 
increasing the incidence of osteoporotic fractures. The cost-utility ratio in this model ranges frorn 
approximately $7,000 to $200,000, depending on the model assumptions, but remains moderate for 
most simulated treatment effects. We conclude that Markov modelling is an appropriate method 
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of summarizing the COPD literature to reach clinically useful estimates of the effects of inhaled 




1.1 Chronic Obstructive Pulmonary Disease 
Chronic obstructive pulmonary disease (COPD) is a respiratory disease marked by reduced lung 
function, abnormal inflammatory response, dyspnea (shortness of breath), increased sputum pro-
duction, chronic cough, and exacerbations (triggered most commonly by noxious gases, pollution, 
and infection). The diagnosis of COPD includes the diagnoses of emphysema and chronic bronchi-
tis. According to the National Heart, Lung, and Blood Institute, COPD is the most frequent cause 
of death from lung disease: approximately half of all respiratory-related deaths in 1999 were at-
tributable to COPD [50]. COPD is also an extremely costly disease, accounting for 713,000 hospital 
adrnissions in 1999 [50J and $23.9 billion in economic costs in 1993 [70]. This disease was ranked 
the 12th leading cause of disability-adjusted life years lost worldwide in 1990, but is projected to 
increase its impact to become the fifth such ranked disease by the year 2020 [19]. 
COPD occurs lnore frequently in smokers than nonsmokers, although less than 25% of smokers 
ever develop COPD and more than 15% of deaths attributable to COPD occur in individuals who 
have never smoked [13]. The prevalence of chronic bronchitis varies with age, race, and sex: the 
lowest prevalence is 1.83% among 18-44 year old black males, while the highest prevalence is 7.67% 
among white females age 65 or older. The prevalence of emphysema also varies, ranging from 
0.98% in 45-64 year old black females to 7.37% in white males age 65 or older. Both diseases are 
most common among whites and the aged; however, chronic bronchitis is more prevalent among 
females, while emphysema is more common in males [50]. The general prevalence of obstructive 
lung disease has increased in all age groups during the past quarter century, and a recent NHANES 
III analysis estimated that as many as 24.2 million American adults have COPD [13]. This presents 
a tremendous burden to the health care system, as well as to the families and employers of COPD 
sufferers. 
The treatment strategies for COPD vary with the patient's disease stage and symptomatol-
ogy. As shown in Table 1.1, the most common treatments include smoking cessation counselling, 
short- and/or long-acting bronchodilators, pulmonary rehabilitation, inhaled corticosteroids (I CS), 
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Table 1.1: COPD staging and treatment strategies 
Stage Disease Characteristics Recommended Treatment 
All Avoid risk factors 
Influenza vaccination 
Smoking cessation 
Stage 0 Normal spirometry 
At risk Chronic symptoms 
Stage I FEVl/FVC~ 70% Short-acting bronchodilator when needed 
Mild FEV 1 2:: 80% pred. 
Stage II FEVl/FVC::; 70% Regular bronchodilator use 
Moderate 50%~FEV 1 < 80% pred. Pulmonary rehabilitation 
Stage III FEVl/FVC~70% Regular bronchodilator use 
Severe 30%~FEVl < 50% pred. Pulmonary rehabilitation 
Inhaled corticosteroids if repeated exacerbations 
Stage IV FEVl/FVC~70% Regular bronchodilator use 
Very severe FEV 1 < 30% pred. OR Pulmonary rehabilitation 
FEV 1 < 50% pred. with Inhaled corticosteroids if repeated exacerbations 
chronic respiratory failure Long-term oxygen therapy 
Consider surgical options 
AbbreViatIOns: FEV 1, forced eXpIratory volume In one second; FVC, forced vItal capacIty; pred., predIcted 
From: Global Strategy for the Diagnosis, Management, and Prevention of COPD [19] 
and home oxygen therapy. Exacerbations of COPD (increases in dyspnea and sputum quantity or 
purulence that necessitate additional treatment) are usually treated with antibiotics and oral glu-
cocorticoids, and may require hospitalization with ventilatory support, depending on their severity. 
These temporary periods of worsened COPD present a great physical and psychological burden to 
the patient, often preventing him from participating in typical daily activities, and are the greatest 
contributor to the direct medical costs of the disease [41]. 
Of the primary therapies described above, one has provoked considerable debate in the pul-
monology community. Multiple clinical studies [56, 62, 57, 77, 9J have found that ICS use reduces 
the frequency of exacerbations. However, a recent meta-analysis [37] demonstrated that ICS ther-
apy docs not slow the decline of FEV 1 (forced expiratory volume in one second), the primary 
clinical marker of COPD, while a different meta-analysis drew the opposite conclusion [17]. This 
controversy was aggravated by several studies which demonstrated either an increase in osteoporotic 
fractures or an accelerated loss of bone density among ICS users [79, 24, 74]. A meta-analysis of the 
relevant literature found that ICS use is not significantly associated with bone density loss [48], but 
no meta-analysis has been conducted to examine the effect of ICS on fracture incidence, perhaps 
because of the limited number of studies of that relationship. Other side effects of ICS therapy 
arc similar to those of oral glucocorticoid use, and may include cataracts, skin thinning (associated 
with bruising), oral candidiasis, and oropharyngeal irritation [62]. ICS therapy is common alnong 
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eOPD patients, despite FDA approval for use in eOPD having occurred only in 2004: a retrospec-
tive analysis published in 2000 observed that approximately 3% of Stage I, 15% of Stage II/III, 
and 61 % of Stage IV eOPD patients use leS [12] A similar study of 1,510 patients in Spain found 
that 41.8%, 59.4%, and 68.4% of mild, moderate/severe, and very severe COPD sufferers used IeS 
during one year [42]. Because of the high prevalence of smoking in the eOPD population, and the 
disease's effects on activities of daily living that commonly result in a reduction in exercise capacity, 
COPD patients tend to have reduced bone mass compared to healthy individuals, and may already 
have an increased risk of osteoporotic fractures. Given that the effects of ICS use on bone health 
Inay, in the worst case, have severe effects on health-related quality of life and direct medical costs, 
while having no effect on the primary clinical marker of disease progression, it is only natural to ask 
whether the risks of leS use outweigh the benefits. This is the question that our research proposes 
to address through the application of discrete-time stochastic process models. 
1.2 Specific Aims 
The Specific Aims of this research are to demonstrate the utility of stochastic models in the exarn-
ination of clinical issues relating to the treatment of chronic obstructive pulmonary disease, by 
1. Developing and implementing a Markov model describing the impact of inhaled corticosteroids 
on the short-term quality of life and direct medical costs of individuals with chronic obstructive 
pulmonary disease, and 
2. Developing and implementing a Markov model describing the impact of inhaled corticos-
teroids, including the putative side effect of osteoporotic fractures resulting from corticosteroid-
induced bone density reduction, on the long-term quality of life and direct medical costs of . 




2.1 Markov Models 
Stochastic models are commonly used to model biological or medical events in computer-simulated 
populations, particularly when in vivo studies of the events would be excessively costly, time-
consuming, or unethical. When the individuals in a population can be described as occupying one 
of several mutually exclusive states, state-transition models allow a researcher to simulate the flow 
of individuals through those states under different sets of assumptions. The Markov chain, which 
assumes that the current state of an individual depends only on his immediately prior state (the 
Markovian assulnption), is a popular type of state-transition lllodei. Markov chains have been used 
to simulate a wide variety of events, from epidemic/zoonotic dynamics [40] to the cost-effectiveness 
of drug treatment in individuals with HIV / AIDS [31] and sepsis [47]. In each of these applications, 
individuals moved through states such as uninfected/at risk, infected, actively contagious, recov-
ered, and dead, with the pre-specified probability of moving from one state to another based on 
either existing experimental evidence or hypothetical estimates. A Markov chain is partially defined 
by a transition matrix, which describes the probability of moving from one state to any other state 
during one time-cycle of the model. The transition probabilities within the matrix can be varied to 
simulate different conditions: for example, in a model of influenza spread, the probability of moving 
from an uninfected state to an infected state might be reduced through vaccine administration. In 
this situation, a. researcher with pertinent information from a clinical vaccine trial could simulate 
the effects of vaccination programs on the spread of the virus, something that would be extremely 
difficult to study in vivo on a large scale. 
Discrete-time Markov models are defined by a transition matrix P and initial state X o. To-
gether with the Markovian assumption, these matrices completely describe the initial distribution 
of the population across model states. Because discrete-time Markov models are iterative in nature, 
and shift the population between states with each iteration, the time frame represented by each 
iteration must be chosen. Typically, an iteration is assumed to represent the average length of time 
during which an event of interest will occur, and the transition matrix will be populated based on 
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the time represented by one iteration. For example, researchers modelling influenza spread might 
consider each iteration to represent two weeks, an normal period of illness for one individual. Once 
the time frame of each iteration has been determined, the transition Inatrix P must be populated, 
i.e. the probability of moving from one state i at time n to any other state j at time n + 1, denoted 
Pi~n,n+l), must be estimated from data, published literature, or expert opinion. 
The form of the probabilities in P will vary depending on the process under study: if p.(~,n+l) 
'lJ 
does not vary over the complete time period under study, then the model is considered stationary, 
or time-invariant. However, if pLn,n+l) changes over time, as might occur in the context of an age-
related illness, then the probabilities can be constructed as a function of the number of iterations 
completed, and the model is referred to as non-stationary, time-variant, or time-dependent. For 
example, in any long-term model that allows all-cause death, the probability of death should be 
allowed to change over time as the age of the simulated cohort increases. This characteristic allows 
greater flexibility in the assumptions considered during the construction of the model. 
There are two types of model states: transient and absorbing. As the name suggests, a state i is 
absorbing if pLn,n+l) = 0 'r;j jf-i, or if ~~n,n+l) = 1 for j = i. Once an absorbing state is entered, 
it cannot be exited. In models of clinical events, death is probably the most common absorbing 
state. If a state is not absorbing, it is transient and may be revisited, depending on the model con-
struction. Differentiation between these state types becomes useful during analysis of the Markov 
chain. 
As described, a Markov chain can provide valuable information about the flow of a population 
between model states under different assumptions. However, these models' informative capacity 
can be vastly extended by applying weights to each state. In models of medical events, these 
weights often represent patient health-related quality of life or the costs incurred by a health event. 
Each population in a given state is multiplied by the state's weighting function and summed over 
the iterative process, producing estimates of quality-adjusted years lived or total costs incurred. 
Specifically, when g(i) is the weighting function for the transient state i, in a model with r transient 
states, Wi is the mean sum of the weights for state i over T iterations: 
r-l 
g(i) + L PijWj for i = 0,1, ... ,r - 1. 
j=O 
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The system of r equations describing Wi, i = 0,1, ... ,r - 1 can then be solved to obtain a set of 
solutions describing the mean sum of weights for a given state. For a model with an infinite number 
of iterations, this method of algebraically obtaining solutions permits the analyst to estimate quan-
tities such as the average time until death, the number of exacerbations or fractures experienced, 
the quality-adjusted life years lived, and costs incurred, under a variety of assumptions. In addition, 
it is simple to simultaneously draw all of the transition probabilities from distributions (based, for 
example, on reported 95% confidence intervals) to obtain estimates of variability of these outcomes 
in a Monte Carlo procedure. 
When a Markov model does not have an infinite number iterations, instead having a finite time 
horizon, the method of algebraic solution derivation no longer applies. In this case, the process of 
weighting is still valid. However, instead of solving a system of equations to find the mean sum of 
weights for a model state, that sum is computed directly through the application of some simple 
matrix mathematics. Specifically, where Xo describes the initial population distribution among 
the model states and P is the transition matrix, Xopi describes the population of each state dur-
ing iteration i. The sum of the weights in a given state over n (a finite number) of iterations 




Put simply, this function multiplies the number of people in a model state by the weight assigned 
to that state, and then sums the result over a specified number of iterations to yield the sum of the 
weights incurred by the entire cohort during the time frame of the model. 
2.2 Cost-utility Models of COPD 
Two cost-effectiveness models of COPD progression and exacerbations have been published recently. 
The first, a model by Sin, Golmohammadi, and Jacobs [10], included model states for three stages 
of COPD, an exacerbation state, and a death state. Each model iteration represented the passing 
of three months. This analysis was undertaken from the societal perspective, including costs to 
the patient and society as well as direct costs to the medical system. The model drew parameter 
values from literature, and permitted ICS to affect mortality, exacerbation rates, and costs. The 
authors concluded that ICS use resulted in a cost-utility ratio of $17,000 per quality-adjusted life 
year gained among patients with stage II-IV COPD, and a ratio of $11,100 per quality-adjusted 
life year gained among stage IV patients. 
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A different model by Spencer and co-workers [45] included model states for three stages of 
COPD, exacerbations, and death. The model was informed by an analysis of the TRISTAN (TRial 
of Inhaled STeroids ANd long-acting fJ-agonists) clinical trial. The model assumed that ICS could 
affect exacerbation risk, disease progression, mortality, and health status, but did not state what 
these effects would be, citing "both current evidence and data that may become available in the 
future." The authors concluded that ICS use resulted in cost-effectiveness ratios of $11,125 to 




3.1 Model of Disease Progression 
Figure 3.1: Schematic: Model of COPD Exacerbations and Disease Progression 
The Markov model to examine COPD progression and exacerbations over three years allows wors-
ening of disease, movement between stable and exacerbation states, exacerbation relapses, and 
deaths attributable to either COPD or non-COPD causes. The parameters describing disease pro-
gression and mortality vary with cohort age category, and health-related quality of life is allowed to 
vary with time within each simulation. This model also permits the simulated population to move 
between smoking and ex-smoking sub-models in a reversible jump construction: the submodels 
have identical structure, but their transition matrices differ according to differences in parameter 
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values between smokers and ex-smokers. The submodel structure (not showing the smoking and 
ex-smoking hierarchy) is described graphically in Figure 3.1. 
3.2 Model of Osteoporotic Fractures 
The Markov model simulating the effects of leS on bone health over a 20-year time horizon is 
described graphically in Figure 3.2, and the corresponding transition matrix may be found in Ta-
ble 3.1. This model permits the population of never-fractured individuals to experience osteoporotic 
fractures of the hip (potentially multiple times), and move between states of recovery and fracture, 
before entering the death state. The parameters guiding mortality and fractures have been allowed 
to vary with time, and mortality also varies according to eOPD stage. The model output allows 
examination of the time spent in a fractured model state, time until death, total costs incurred, 
and quality-adjusted life years lived. 
Figure 3.2: Schematic: Model of Osteoporotic Fractures in the eOPD Population 
Table 3.1: Transition matrix: Model of Osteoporotic Fractures in the eOPD Population 
State at time n + 1 
Never Recovering 
Fractured Fractured Fracture Dead 
Never 
1 - ¢I(t) - )'1(8) ¢I (t) 0 Al (s) 
Fractured 
Fractured 0 0 1 - A2(s, t) A2(s, t) 
Recovering 
0 ¢2(t) 1 - ¢2 ( t) - Al ( S ) Al (s) 
Fracture 
Dead 0 0 0 1 
s: COPD stage; t: tIme (age) 
The).. and ¢ functions describe deaths and fractures, respectively. 
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3.3 Analysis Methods 
The Markov models simulate the dynamics of COPD cohorts via the processes described in Sec-
tion 2.1. All simulations were performed in MatLab Version 6.5 (The MathWorks, Inc.). 
In an economic analysis that uses previously published costs, it is necessary to inflate all costs 
to represent dollar values from the same year. When the cost in the target year is denoted as 
Costr, and the cost in the original year is denoted as Casto, this inflation is accomplished via the 
following formula: 
CPIT 
CostT = Casto' -C ' 
Plo 
where CPIT represents the Medical Costs Consumer Price Index (CPI) [7] for the target year. For 
example, the Medical Costs CPI for 1994 was 211.0, and for 2004 was 310.1. Thus, a cost of $1,000 
in 1994 would inflate to $1,000 * (310.1/211) = 1,470 in 2004 dollars. 
In many studies, cost discounting is also applied to simulate the perceived higher value of 
money in the near future relative to the more distant future. The standard discount rate in the 
U.S. is 3%. The process of discounting is applied at each iteration of a !vlarkov model following the 
starting state via the following formula: 
Discounted cost = _1_. (Starting cost) , 
1.03'l 
where i denotes time or the number of model iterations. 
A critical quantity in cost-utility models is the quality-adjusted life year, or QALY. The QALY 
is simply the numerical result of adjusting one year of life by the quality of life weight for that time 
period. In the U.S., an individual can live up to one QALY in a year, and a lower QALY lived 
represents a lower level of quality of life. 
Once the total costs and the sum of quality of life weights (QALYs) have been computed over 
the lifetime of the model, the cost-utility ratio can be constructed. This quantity describes the 
change in costs that is associated with the gain of a single QALY, and is cornputed as: 
CUR = COSTlcs - COSTp 
QALYS1CS - QALYSp 
The cost-utility ratio will vary depending on the effects of the treatment being modelled. If 
the treatment increases both costs and QALY s lived, the CUR will reflect the expenditure per 
QALY gained. However, if the treatment increases costs and decreases QALY s lived, the medical 
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system will be paying to reduce the number of QALYs lived by a patient; this combination of 
factors implies that the treatment may not be of much value. If the treatment decreases costs and 
increases QALYs lived, the (negative) CUR describes the cost savings per QALY gained; however, 
it is traditional to report the cost differences and increases in life years in this situation, rather than 
the CUR. Finally, if the treatment reduces both costs and QALYs lived, the CUR is not considered 
to reflect a clearly beneficial treatment. 
11 
Chapter 4 
'Transition Probabilities: Model of Disease Progression 
A Markov chain is partially defined by the transition matrix P, which defines the probability that 
an individual moves from one state i at time n to any other state j at time n + 1. This probability 
is denoted Pi~n,n+l), and must be estimated from data, published literature, or expert opinion. The 
Markov model of COPD over three years allows worsening of disease, movement between stable 
and exacerbation states, and deaths attributable to either COPD or non-COPD causes, and many 
of the parameters are allowed to vary with time and/or COPD stage. This model also permits the 
simulated population to move between smoking and ex-smoking sub-models in a reversible-jump 
construction; the submodels have identical structure, but their transition matrices differ. In this 
chapter, the clinical, epidemiological, and economic literature pertaining to the derivation of the 
lllodel's transition matrix and weighting functions is reviewed, and the resulting model parameters 
are presented. 
4.1 Transitions to Non-COPD Death 
Table 4.1: Mortality rates per 1,000 person-years, by age group [16] 
45-54 55-64 65-74 
Male Ex-smokers 
Male Heavy Smokers 
Female Ex-smokers 
Female Heavy Smokers 
3.5 12.0 32.2 
9.3 21.6 48.5 
3.0 7.9 19.4 
5.5 14.6 33.8 
Since the recognition of increased mortality among smokers in the 1960s, few publications have 
included separate mortality tables for smokers and ex-smokers. Prescott's [16] analysis of three 
prospective population cohorts compared smoking-related mortality between men and WOlnen. The 
mortality estimates for male and female smokers and ex-smokers are found in Table 4.1. Because 
these mortality rates are all-cause, and include deaths from COPD, they were reduced by the 
percent of deaths attributed to non-cancer respiratory disease to yield the mortality rates that 
might occur in the absence of COPD (Table 4.2). Unfortunately, the respiratory mortality rates 
were not supplied by age category, so the burden of mortality was assumed to be equal across ages. 
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The transition probabilities geneyated from these rates, assuming an exponential model, may be 
found in Table 4.3. 
Table 4.2: Mortality rates per 1,000 person-years, adjusted for respiratory disease 
45-54 55-64 65-74 
Male Ex-smokers 
Male Heavy Smokers 
Female Ex-smokers 













Table 4.3: Transition probabilities for the move to non-COPD death 
4554 55-64 65-74 
Male Ex-smokers 
Male Heavy Smokers 
Female Ex-smokers 
Female Heavy Smokers 













The movement from Stage II/III COPD to Stage IV is defined clinically by a decrease in FEV 1 to 
below 30% predicted or FEV 1 below 50% predicted in the presence of chronic respiratory failure 
(Table 1.1). In an ideal model, the transition between these two stages would be derived from 
a rllultivariate model describing the probability of either of those events. This type of model is 
beyond the scope of this project and the data at hand; thus, the transition was modelled strictly on 
projected declines in FEV 1, which vary according to sex [35] and smoking status [23], and possibly 
with ICS use [37]. Using an estimate of the distribution of % predicted FEV 1, population equations 
for predicted FEV 1, and known rates of lung capacity decline in COPD sufferers, the transition was 
estimated as the probability that an individual with % predicted FEV 1 between 30% and 80% will 
lose sufficient function during two weeks (one model iteration) to drop his % predicted measurement 
below the staging threshold of 30%. 
The distribution of % predicted FEV 1 was estimated from NHANES II data [20]. In an attempt 
to exclude individuals without respiratory disease, the dataset was restricted to include only those 
participants with a FEV l/FVC ratio of less than 70%. SAS PROC UNIVARIATE [69] was then 
used to fit a distribution to the data according to gender and age subgroups; the best-fitting 
distributions for men and women were Beta(3.63, 1.36) and Beta(3.7, 1.54), respectively, but the 
parameters of the distribution varied by age group. Histograms of these data, and their overlaid 
Beta distributions, may be found in Figure 4.1. 
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Figur 4.1: re nt pr diet d FEV 1 with overlaid Beta di tribution for (a) Females 45-54 B ta(3.25 
1. ) (b) Mal 45-54, Beta(4.99, 1.55), (e) Felnale 55-64 Beta(3.73, 1.6) (d) Mal 55-64 
B t (3. 5 1.52) (e) B male 65-74, Beta(4.56, 1.91) (f) Male 65-74 Beta(3.25 1.27). 
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Table 4.5: COPD yearly exacerbation rates in clinical trials and observational studies 
Author/Study Rate Study Population 
ISOLDE [57, 56] 0.99 Fluticasone propionate (FP) users 
1.47 Moderate/severe COPD, FP users 
1.32 Placebo users 
1.75 Moderate/severe COPD, placebo users 
1.05 Placebo users who completed trial 
1.69 Placebo users who did not complete trial 
Lung Health Study [24] 0.99* COPD hospitalizations: triamcinolone users 
2.1 * COPD hospitalizations: placebo users 
1.3* ER visits: triamcinolone users 
1 * ER visits: placebo users 
1.2* Outpatient visits: triamcinolone users 
2.1 * Outpatient visits: placebo users 
Calverley [55] 1.38 Moderate/severe COPD, budesonide + formoterol users 
1.85 Moderate/severe COPD, formoterol users 
Calverley [53] 0.97 Mild exacerbations: salmeterol + fluticasone users 
0.46 Moderate/severe exacerbations: salm. + FP users 























Moderate/severe exacerbations: salmeterol users 
Moderate/severe COPD, budesonide users, years 1 & 2 
Moderate/severe COPD, placebo users, years 1 & 2 
Moderate/severe COPD, budesonide +. formoterol users 
Moderate/severe COPD, formoterol users 
Moderate/severe COPD, beclomethasone users 






CO PD "exacer bators" 
* Per 100 person-years 
and 86% were moderate or severe. Among FP users, 38% of exacerbations were mild, and 60% were 
moderate or severe. In this study, a mild exacerbation was one that was self-managed, a moderate 
exacerbation required treatment by a physician or on an outpatient hospital basis, and a severe 
exacerbation required hospital admission. In a study by Seemungal and others [75], prednisolone 
(oral glucocorticoid, an indicator of increased exacerbation severity) was given to 27.3% of partici-
pants who experienced 2 or more exacerbations in the study period, antibiotics were given to 85.6%, 
antibiotics and oral steroids to 25%, and no treatment was needed by 12.1 %. A different study 
by this author [76] found that 16% of exacerbations were severe enough to require hospitalization. 
Finally, a pooled analysis of two clinical trials [32] in stable COPD found that 10% of exacerbations 
were severe, 47% were moderate, and 43% were mild. 
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Table 4.6: Transition probabilities for the move to an exacerbation 
II/III moderate IV moderate 
II/III mild or severe IV mild or severe 
Placebo 0.00965 0.0578 0.0128 0.0763 
Ies 0.0182 0.0296 0.0243 0.0392 
The last exacerbation-related unknown in the Markov model concerns the effects of smoking on 
the frequency and severity of exacerbations. The reversible jump model, which permits transitions 
between smoking and ex-smoking submodels, allows the incorporation of information regarding dif-
fercnces in these exacerbation parameters according to smoking status. Surprisingly, these effects 
are rather unclear. In one observational study of prognostic factors for hospitalization for an acute 
exacerbation, Kessler and colleagues [59] found that smoking did not increase the likelihood of ad-· 
mission; age, % predicted FEV 1, and comor bidity also failed to significantly predict hospitalization. 
Similarly, in the analysis by Oostenbrink [32], smoking status did not significantly predict time to 
hospitalization. However, Garcia-Aymerich's analysis of patients admitted for exacerbation [27] 
found that current smokers were actually at a significantly decreased risk of readmission relative 
to ex-smokers (hazard ratio 0.58, 0.41-0.82). A study by this research group of risk factors for 
admission [28] also found that smokers enjoyed a decreased risk; however, it is possible that some 
participants became ex-smokers as a result of severe symptoms that predisposed theIn to relatively 
frequent hospitalization. Finally, Donaldson's [22] four-year cohort saw that frequent exacerbators 
(more than 2.92/year) were more likely to be current smokers (marginally significant, p = 0.056). 
It is clear that further study is necessary to elucidate the effects of smoking on exacerbations. 
Based on the studies summarized in Table 4.5, the exacerbation rates were assumed to be 
1.8/year and 2.4/year in Stages II/III and IV, respectively. To distribute these between mild and 
moderate/severe exacerbations, the model assumes Paggiaro's [54] observed severity distribution, 
as well as a 30% reduction in total exacerbations for IeS users. Because the effect of smoking on 
exacerbations is highly ambiguous, with insufficient evidence to support claims of a difference be-
tween smokers and ex-smokers, the exacerbation-related parameters of the smoking and ex-smoking 
submodels were left identical. The transition probabilities to exacerbation states are summarized 
in Table 4.6. 
The rate of exacerbation treatment failures (re-occurrence of an exacerbation soon after re-
covcry) is significant. While few studies explicitly reported the rate of exacerbation relapse, the 
rate is believed to fall between 10% and 25%. For example, a study by Miravitlles [41] found that 
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21 % of exacerbations relapsed, with 10.1 % of the relapses requiring treatment in an emergency 
department or hospital admission. These figures are directly applicable to the Markov framework 
with the additional imposition of the assumption that the relapse rate is the same for mild and 
moderate/severe exacerbations. Therefore, the probability of transition from a mild exacerbation to 
a moderate/severe exacerbation is 10.1%, and the probability of remaining in a mild exacerbation 
is 10.9%. Likewise, the probability of remaining in a moderate/severe exacerbation is 10.1 %, and 
the probability of relapsing to a milder exacerbation is 10.9%. The remainder of the exacerbated 
cohort, after accounting for deaths, will move back to the stable COPD state. 
4.4 Transitions to COPD Death 
This Markov model assumes that all deaths attributable to COPD originate from the moder-
ate/severe exacerbation state. Thus, estimation of the probability of transition to COPD death 
requires knowledge of death rates among individuals with a moderate or severe exacerbation. Un-
fortunately, few studies report this outcome. Afessa's [4] study of causes of death among individuals 
with COPD admitted to the hospital found a 15% mortality rate when considered on a per-admission 
basis, and a 21% mortality rate on the per-person basis. These percentages were observed among 
individuals with severe exacerbations, and almost certainly overestimate the likelihood of death in 
a group that includes moderate exacerbations (such is the case in this model). However, death 
rates were not reported for a group experiencing moderate/severe exacerbations. Therefore, the 
model will assume that severe exacerbations result in 15% mortality, but the results will be explored 
under a variety of assumptions regarding the makeup of the moderate/severe exacerbation group: 
a mortality rate of 5% reflects a group that is 2/3 moderate, and a mortality rate of 10% reflects 
a group that is 2/3 severe. 
4.5 Reversible Submodel Jumps 
The full Markov model contains two submodels that are identical in structure, but represent the 
different characteristics of smokers and ex-smokers. Because smoking is an addiction with an 
extremely high rate of recidivism, this structure yields a more clinically realistic model than one 
that assumes a cohort consisting solely of smokers, nonsmokers, or ex-smokers. The model assumes 
that approximately 85% of ex-smokers relapse to smoking during one year; this recidivism rate 
has been lowered from common estimates to reflect the likely impact of poor respiratory health on 
ex-smokers' determination to not relapse into smoking. As observed in Pauwels's study of lCS in 
smokers [60], 10% percent of smokers are assumed to quit smoking during one year. 
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While the model is very flexible, some restrictions were placed on model jumps to simplify 
the modelling process. Ex-smokers were permitted to relapse during a move to a stable (non-
exacerbation) state. Smokers were permitted to quit smoking during a move to any stable or 
exacerbation state. 
4.6 Cost Weights 
COPD is an extremely costly disease; however, few studies of the direct costs of COPD [12] have 
been conducted in the United States. Because standards of care and cost distributions across care 
components differ between countries, it is generally unwise to combine cost information from studies 
from different countries. Thus, the portions of these models pertaining to the costs of COPD at 
different stages will rely on one study. 
For the short-term model of COPD progression and exacerbations, costs for medical procedures, 
as well as baseline medications costs, were drawn from Hilleman's economic study [12]. The original 
published costs could have been used as baseline costs for different stages of CO PD, except that 
the costs include the cost of ICS therapy. While this is negligible among Stage I patients (less than 
3% of the Stage I patients studied used ICS), the utilization rate was higher among the Stage II/III 
and IV patients studied (11 % and 29% usage, respectively). Thus, the baseline medication costs 
for Stages II/III and IV were adjusted for ICS costs by subtracting 11 % and 29% of the yearly 
IeS cost ($85/month, $1020/year in 2004 [1], CPI adjusted to $694 yearly). Table 4.7 contains a 
description of the costs incurred in each model state. To avoid overestimating the cost incurred 
as the result of multiple continuous stays in an exacerbation state, the total costs incurred at the 
end of the model were adjusted by the number of relapses to remove redundant chest radiographs, 
electrocardiograms, echocardiograms, and high-resolution CT scans. Finally, all costs were inflated 
to their 2004 dollar value using the Medical Care Consumer Price Index [7] and discounted for 
future dollar value. 
4.7 Health-Related Quality of Life Weights 
Several clinical trials of ICS in COPD have assessed health related quality of life (HRQoL, or QoL) 
during their study periods, and some purely observational studies have also been implemented to 
describe patient HRQoL regardless of drug treatment. Many of these recent HRQoL assessments 
were carried out in conjunction with cost analyses in European countries. For the models formed 
in this thesis, only estimates of HRQoL taken from studies that used a respiratory disease-specific 
questionnaire were considered, as the general questionnaires are often not sensitive to the changes 
in HRQoL that accompany respiratory disease events. The most commonly used disease-specific 
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Table 4.7: Costs incurred in each model state 
Stable II/III Exac. IV Exac. 
Procedure II/III IV Mild Severe Mild Severe Cost 
Baseline medication, yearly X X X X X X 560/535* 
Prednisone X X X X 5 
Azithromycin X X X X 60 
Clinic visit 2/yr. 4/yr. xl xl 35 
Oxygen therapy X X 864/2490* 
PFT X X 27 
PFT w / diffusion capacity X X 78 
Hospitalization (daily) x4 x2.9 464 
ICU hosp. (daily) xO.2 x2 804 
Arterial blood gases X X 21 
Chest radiograph X X 56 
CBC X X 7 
SMA-20 blood test X X 16 
Hepatic enzymes X X 21 
Sputum Gram stain X X 11 
Sputum culture X X 24 
Electrocardiogram X X 24 
Cardiac enzymes X X 59 
Echocardiogram X X 402 
High-resolution CT X X 1194 
Total $/iteration, Placebo 61 125 121 3004 126 4874 
Total $ /iteration, IeS 88 152 148 3031 153 4901 
* Denotes different costs for Stages II/III and IV. 
HRQoL questionnaire among COPD studies is St. George's Respiratory Questionnaire (SGRQ). 
This questionnaire contains 3 subscales, which address disease symptoms, activity level, and the 
impacts of the disease; a total composite score summarizes the information contained in these 
subscales. Each subscale and the composite total score fall on a 0-100 scale, on which lower scores 
represent higher respiratory QoL. The SGRQ is a validated scale that has been translated into 
several languages. The findings of twelve studies of HRQoL in COPD patients are summarized in 
Table 4.8. This table describes the total SGRQ scores for COPD patients at different stages of 
disease, under different therapeutic regimens, and in a variety of situations. 
In addition to estimating the difference in HRQoL weights between placebo and lCS users, 
we must estimate weights for the different model states of COPD II/III, COPD IV, and the nlinor 
and major exacerbations stemming from these states. Since QoL is predicted by COPD stage, a 
regression of average HRQoL on average reported FEV 1 was performed, incorporating information 
from all papers summarized in Table 4.8. The regression model estimated that HRQoL drops 
(SGRQ score increases) by 0.488 units per unit decline in % predicted FEV 1. 
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Table 4.8: Studies of Health-Related Quality of Life in COPD 
Author Status SGRQ Total Score 
--------------~~----------------------
Osman LM 1997 [39] Hospitalized 52.7 
Breslin E 1998 [14] Pulm. rehab. candidate 54.2 
Hajiro T 1999 [73] Stages I-IV 36.4 
Burge PS 2000 [56] Placebo 49.9 
Domingo-Salvany A 2002 [3] 
van der Valk 2002 [78] 
Peruzza S 2003 [64] 
Miravi tlles M 2004 [44] 
Andersson I 2002 [26} 
Desikan R 2002 [58] 
Miravitlles M 2002 [43] 
Rutten-van Molken 1999 [46] 
FP (ICS) 47.7 
Finished study alive 
Died during study 
Stage II-IV, FP (ICS) 
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* IB: ipratropium brornide 
The estimates of HRQoL score for individuals with moderate/severe (FEV 1 65% of predicted) and 
very severe COPD (FEV 1 25% of predicted) are 35.73 and 55.25, respectively. 
The HRQoL scores for a total of four minor and major exacerbation states (2 exacerbation 
severities for each stage of COPD) must also be estimated. Andersson [26] examined QoL for 
one year following hospitalization for severe exacerbation. Among the survivors of the study, the 
mean SGRQ total score at inclusion (5-7 days after initiation of treatment) was 54 (46-62). This 
decreased (HRQoL increased) to 49 (38-60) after 3 months and remained steady until the 12-month 
evaluation (40---57). The authors concluded that the increase in HRQoL observed was both "an 
effect of the exacerbation and partly of the hospitalization." Thus, a similar reduction in HRQoL 
(absolute change of 9.25%) will be applied to estimate scores for the major exacerbation states, 
and a smaller reduction of 5% to estimate scores for the minor exacerbation states (which will not 
require hospitalization). 
Because of the extended time horizon of the models examined herein, changes in HRQoL over 
time must be taken into account. While no extremely long-term studies of HRQoL changes in 
COPD populations exist, the randomized, double-blinded, placebo-controlled ISOLDE trial [56] 
did follow changes in HRQOL for three years using the SGRQ. They observed that HRQoL scores 
increased (HRQoL declined) at the rates of 3.2 units per year for patients using placebo and 
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2.0 units per year for those assigned to the lCS fluticasone propionate (FP) (difference in rates 
p = 0.004). This finding of higher HRQoL among lCS users is supported by the COPE study [78], 
which examined the effects of discontinuing lCS (FP) in a randomized double-blinded environment 
with 244 patients with moderate to severe COPD. At baseline (before randomized discontinuation), 
the mean SGRQ total scores were 38.2 and 34.3 in the placebo and FP groups, respectively. After 
6 months, after adjusting for covariates, there was a significant difference between the FP and 
placebo arms of 2.48 (0.37--4.58) units in favor of FP. Finally, in a study by Miravitlles [44J, the 
QoL of the participating COPD patients improved over the 2-year study period. However, because 
the improvements occurred mainly during the first 6 months, remaining constant thereafter, they 
will be considered an an effect of improved care; the possibility of improvements in HRQoL over 
tiIne will not be considered by the models herein. A QoL weighting function that summarizes the 
information above into weights appropriate for 2-week model increments may be constructed as 
follows: 
QT = 1.03-T [Qo - M * T] 0.9075s0.95P , where 
• QT represents the HRQoL weight for a given state at time T 
• Qo is the initial HRQoL weight; this varies by COPD stage as described above 
• M represents the difference in HRQoL decrease between lCS users and lCS non-users, and 
may be assigned values to reflect no difference (M = 0.000123), a small difference (M = 
0.0000769), or a large difference (M = 0.0000269) 
• S=1 for major exacerbation states, S=O otherwise 
• P=l for minor exacerbation states, P=O otherwise 
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Chapter 5 
Transition Probabilities: Model of Osteoporotic Fractures 
5.1 Transitions from Never Fractured to Died 
To date, relatively few clinical trials or epidemiologic surveys have examined COPD-specific mor-
tality. The published mortality data are based primarily on clinical trials of ICS in COPD, prospec-
tive cohorts, and some database studies. With few exceptions, the data describe all-cause mortality 
rather than COPD-specific deaths. However, the medications used to treat COPD, specifically ICS, 
are not known to affect the occurrence of other major sources of mortality. 
The ISOLDE trial (cited in [62]) is the only large randomized controlled trial of ICS in COPD 
that has explicitly examined mortality effects. In this three-year study, a small survival advantage 
was shown, with approximately 86% of ICS users and 80% of bronchodilator users (with no ICS) 
surviving at the end of the trial. 
Alsaeedi and coworkers [2] recently published a meta-analysis of the effects of ICS on multiple 
outcomes of COPD. They observed a non-significant 16% reduction in mortality associated with 
the use of ICS. 
A study of mortality among COPD patients hospitalized for exacerbation [4] found a hospital 
mortality rate of 15% when considered at the per-hospitalization level, and 21% when considered 
at the per-person level. 
One particularly informative study is Domingo-Salvany's prospective cohort of COPD suffer-
ers in Barcelona, Spain [3]. Over a mean followup period of 4.8 years in this cohort, 106 deaths 
were observed among 312 individuals. Among those deaths, 48 were attributable to respiratory 
causes, and 38 deaths were specifically coded to COPD. Participants with stage I (mild) COPD 
had a 4-year survival rate of 89% (84%-95%), Stage II/III (moderate and severe) participants had 
73% 4-year survival (63%-84%), and Stage IV (very severe) sufferers had 4-year survival of 600/0 
(51 %--70%). The distribution of mortality causes in each stage was not described; thus, it is not 
possible to know what proportion of deaths within each severity level were due to COPD instead 
of other competing hazards. 
24 
Table 5.1: Observational studies of ICS effect on COPD mortality 








Immortal time bias present 
Overall hazard ratio 0075 
Low dose 0.77 
Medium dose 0.48 
High dose 0.55 
Overall hazard ratio 0.62 
Hierarchical ITT 0.66 
Conventional ITT 0.75 
Overall risk ratio* 0.69 
Analysis corrected for bias 
Overall hazard ratio 0.87 
Low dose 0.75 
Med/high dose 0.91 
Low doset 0.96 
Med/high doset 0.86 
Overall risk ratiot 1.00 
















ITT, intent to treat analysis, * time-fixed analysis, t time-dependent analysis 
The following studies are observational studies which relied on electronic records gathered by 
pharmacies or state/national health organizations. The proper method of statistical analysis for 
these data is still under discussion. Some studies have used analytic methods that may have led to 
the creation of ~~immortal time," in which the amount of study time prior to exposure is included 
in the followup time. This artificially inflates the period of time during which the exposed partic-
ipant (in this context, lCS user) was at risk of death, resulting in an underestimate of the death 
rate among exposed participants. Several database studies have been conducted to date, using a 
variety of methods in an attempt to explore the effects of immortal time bias and extract the true 
effect of lCS on COPD mortality. Generally, the results of these studies can be divided into two 
groups: those which claim to adjust for immortal time bias, and those which do not adjust. As 
shown in Table 5.1, this division is equivalent to that obtained by comparing the analyses which 
fail to demonstrate an effect, and those which demonstrate a statistically significant reduction in 
mortality attributable to lCS use. 
A prospective cohort [80] based in Seattle, Washington used the electronic medical and phar-
rnacy records of 8,033 participants to form several hazard models of the effect of ICS on patient 
rnortality. Of the total sample, 2,686 participants were classified as leS users. The followup period 
extended to three years, with a mean followup of 544 days. In the initial proportional hazards 
analysis similar to those performed by Sin [11] and Soriano [33, 34], Fan found no evidence to sup-
25 
port an association between ICS use and death, as the hazard ratio of death in ICS users relative to 
nonusers was 0.87 (0.72-1.05). Stratification by ICS dose also yielded no association. In a separate 
time-dependent analysis designed to avoid immortal time bias, there was still no significant effect at 
either dose level. Restriction of the analysis to participants without a concurrent asthma diagnosis 
increased the hazard ratio slightly at both dose levels, but did not alter the significance of the 
results. 
In an analysis that compared time-fixed and time-dependent survival analysis techniques [66}, 
Suissa observed an adjusted rate ratio of 1.00 (0.79--1.26) of mortality among ICS users, relative 
to bronchodilator users. Another observational study [67} by Suissa analyzed data from the com-
puterized databases of Saskatchewan Health (Saskatchewan, Canada) in three different manners to 
demonstrate the effects of immortal time bias. This study found that when bias was accounted for, 
the relative risk of mortality was 0.94 (0.81---1.09) among ICS users, compared to nonusers. How-
ever, when statistical analysis methods permitting immortal time bias were used, the resultant risk 
ratios were consistently and significantly less than unity, ranging from 0.66 to 0.85, with confidence 
intervals collectively covering the interval (0.57-0.98). 
Soriano's 3-year study of survival among fiuticasone (leS) and/or salmeterol (,B-agonist, not an 
ICS) users [33} drew data from the UK General Practice Research Database. The reference group 
(,a-agonist users) experienced 63.6% survival over three years; the yearly rates varied slightly by 
sex. After adjusting for covariates including sex, age, year of entry, smoking, comorbidity, history of 
asthma, and oral steroid use, Soriano found a hazard ratio for mortality of 0.62 (0.45-0.85) among 
fiuticasone propionate users, compared to ,B-agonist users. A later study by the same research 
group [34] examined the effect of ICS and/or long-acting ,B-agonists (LABA) on the likelihood of 
death within one year after a first COPD-related hospitalization. In this study, they found that 
death occurred within one year of follow-up in 24.3% of the reference group and 17.1% of ICS-only 
(no LABA) users. 
Finally, a database-sourced study [11] based in Alberta, Canada found that after adjusting for 
covariates (age, sex, co morbidity, ICU stay, and use of other pulmonary medications), ICS users 
were 75% as likely to die as ICS nonusers (0.68-0.82). Stratification by dose indicated that higher 
doses were more effective in reducing mortality. The control group consisted of individuals who 
were hospitalized for COPD, but did not subsequently receive an ICS prescription; this is not tech-
nically equivalent to the bronchodilator control common to other studies. It should be noted that 
this study, as well as those by Soriano (above), have been argued to suffer from immortal time bias. 
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Table 5.2: Transition probabilities between never fractured and dead states 
Stage II/III Stage IV 
RR= 1.0 0.0653 0.0952 
RR= 0.85 0.0558 0.0815 
RR= 0.70 0.0462 0.0676 
The decision model's parameters were thus selected to represent a range of observed mortality 
effects (relative risk of 1.0, 0.85, and 0.70), as these cover the range of effects shown in Table 5.1. 
To estimate the yearly probability of death, these risk ratios were applied to Domingo-Salvany's 
estimates of mortality [3J (the only study that presented overall mortality by disease stage). Based 
on the 4-year survival proportions r from that study, the transition probabilities p shown in Ta-
ble 5.2, which describe the probability of moving from the never fractured state to the dead model 
state, were computed as p = 1- e(-r/4), assuming an exponential rnodel with constant hazard over 
the 4-year study period. 
5.2 Transitions from Fractured to Died 
Osteoporosis, the presence of severely lowered bone density, is a disease that is often recognized 
only after a bone fracture develops in the absence of appropriate trauma. These fractures occur 
rIlost often in the hip, spine, and wrist/forearm. Many factors contribute to the development of 
osteoporosis, including smoking, diet, comorbid disease, and lack of exercise, but chronic use of 
oral glucocorticosteroids has also been shown to reduce bone density and increase fracture rates. 
In this section, we review the literature describing mortality associated with osteoporotic fractures 
of the hip. 
A five-year study (Edmonton, Alberta, Canada) of differential morbidity and mortality be-
tween five types of osteoporosis treatment medication users who experienced a hip fracture [49] 
found 44% mortality over the full period of study. They observed an odds ratio for mortality in 
fractured males of 3.56 (1.59-7.98) over one year, and 2.58 (1.35-4.95) over five years, relative to 
fernales who experienced a fracture. While there was a trend toward reduced odds of mortality 
among younger participants, the odds ratios were not statistically significant. The presence of three 
or rnore comorbidities was found to significantly increase the odds of mortality in both time fralnes, 
as was the presence of some functional decline. 
A 5-year prospective cohort based in Dubbo, Australia [36] provided highly descriptive esti-
mates of mortality after a fracture. This study by Center and others found that the standardized 
mortality ratio for mortality due to hip fractures was 2.18 (2.03-2.32) in women and 3.17 (2.90 . 
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3.44) in men, compared to their unfractured counterparts. The study also described mortality 
rates for < 1 year, 1-2 years, and 2-5 years post-fracture; unfortunately, the latter rates cannot be 
incorporated into a Markov model without violation of the Markovian assumption. 
A similar five-year followup study [51] of residents of Malmo, Sweden who experienced ver-
tebral, hip, shoulder, or forearm osteoporotic fractures found 22% mortality after a hip fracture 
during the first post-fracture year. In similar findings to those of the Dubbo study, the mortality 
rates decrease steadily with time after their initial increase at the time of fracture. These general 
findings were supported once more by a study examining 30 years of English health database in-
formation [72]. While the English fatality rates are higher than the rates observed in Malmo, the 
results of the two studies are comparable in their other aspects. 
The previous studies have all provided very useful information regarding mortality rates among 
individuals who experienced osteoporotic fractures, However, it is believed that a major portion 
of the mortality is due to comorbidities and not to the fracture itself. In the context of a Markov 
model, it is necessary to use mortality rates specific to the event under examination, or to estimate 
the fraction of deaths that are directly caused by the fracture. Fortunately, one study has derived 
these rates. 
Kanis's study of mortality following hip fractures among 158,589 Swedish residents [29J pro-
duced results generally similar to those of other studies. Like Cree [49], Kanis found higher mortality 
among men than women. They also observed a sharp increase in mortality that decreased slowly 
over several years, as in Center's [36] and Johnell's [51] studies. Kanis estimated that around 24% 
(between 17% and 32%, depending on age) of the mortality during the first year following a fracture 
is attributable to the fracture itself; the rest of the deaths are believed to be due to comorbidity. 
Table 5.3: Mortality during the first year following a hip fracture, Sweden [29] 
Males Females 
Fracture Fracture 
Age Fractures* deaths* % Deaths+ Fractures* deaths* % Deaths+ 
50 0.35 0 0 0.38 0 0 
55 0.59 0 0 0.86 0 0 
60 0.89 0 0 1.52 0 0 
65 1.67 0.1 0.0599 2.73 0.1 0.0366 
70 3.13 0.2 0.0639 5.60 0.1 0.0179 
75 6.09 0.5 0.0821 11.54 0.4 0.0347 
80 11.86 1.1 0.0927 21.60 0.8 0.037 
85 23.07 2.6 0.1127 37.44 2.1 0.0561 
* Rates per 1,000 person-years; + Percent of fractures resulting in death. 
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Table 5.4: Estimated rates of death from COPD 







Death rates per 100 person-years 
The probability of death among individuals who experienced a fracture, computed as the ratio of 
fracture-specific death rates and fracture rates, is found in Table 5.3. 
The probability of moving from the fractured state to the dead state describes the chance that 
an individual with COPD, who has experienced an osteoporotic hip fracture during a one-year time 
span (one model iteration), will die during the following year (the next iteration). As there have 
been no studies of mortality attributable to osteoporotic fractures among COPD patients, these 
transition probabilities must be synthesized from two sources: studies of COPD mortality, and 
studies of osteoporotic fracture mortality. 
Working backward from the transition probabilities p in Table 5.2, the yearly rates of death T 
shown in Table 5.4 are computed simply as T = -In(l - p). Kanis's estimates of the percentage of 
mortality directly attributable to hip fracture allow computation of an approximate relative risk of 
mortality. The mortality rates after hip fracture, computed by the application of the relative risks 
to COPD mortality rates, are shown in Tables 5.5 and 5.6 for males and females, respectively. The 
transition probabilities derived from those rates are contained in the same tables. 
Table 5.5: Deaths after hip fracture among male COPD sufferers 
Mortality Rates Transition to Death State 
Age RR=l RR=0.85 RR=0.70 RR=l RR=0.85 RR=0.70 
65 7.158 6.084 5.01 0.069 0.059 0.049 
70 7.185 6.107 5.03 0.069 0.059 0.049 
75 7.307 6.211 5.115 0.07 0.06 0.05 
80 7.379 6.272 5.165 0.071 0.061 0.05 
85 7.514 6.387 5.26 0.072 0.062 0.051 
65 10.599 9.009 7.419 0.1 0.086 0.072 
70 10.639 9.043 7.447 0.101 0.086 0.072 
75 10.821 9.198 7.575 0.103 0.088 0.073 
80 10.927 9.288 7.649 0.104 0.089 0.074 
85 11.127 9.458 7.789 0.105 0.09 0.075 
MortalIty In deaths per 100 person-years 
5.3 Transitions from Recovering Fracture to Died 
The transition probability for a move between the states of recovering fracture and died describes 
the probability that an individual with COPD who is recovering from a hip fracture will die during 
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Table 5.6: Deaths after hip fracture among female COPD sufferers 
Mortality Rates Transition to Death State 
Age RR=l RR=0.85 RR=0.70 RR=l RR=0.85 RR=0.70 
65 7.0 5.95 4.9 0.068 0.058 0.048 
70 6.874 5.843 4.812 0.066 0.057 0.047 
75 6.987 5.939 4.891 0.067 0.058 0.048 
80 7.003 5.952 4.902 0.068 0.058 0.048 
85 7.132 6.062 4.992 0.069 0.059 0.049 
r-65 10.366 8.811 7.256 0.098 0.084 0.07 
70 10.178 8.652 7.125 0.097 0.083 0.069 
75 10.347 8.795 7.243 0.098 0.084 0.07 
80 10.37 8.815 7.259 0.099 0.084 0.07 
85 10.561 8.977 7.393 0.1 0.086 0.071 
MortalIty In deaths per 100 person-years 
one year. It has been well demonstrated that the increased mortality that occurs after a hip 
fracture declines after the fracture [51, 29, 36]. However, the morc specific analysis by Kanis [29] 
found that the mortality directly attributable to a hip fracture occurs during the first year after the 
fracture, while the remaining increase in mortality was due to comorbidities. Thus, these transition 
probabilities will be equivalent to those for a move from the never fractured state to died. 
5.4 Transitions from Never Fractured to Fractured 
While there is a good deal of literature describing the epidemiology of fractures, few (if any) of 
these were performed in a COPD population. Considering the nature of the information contained 
in the available literature, it is apparent that there are two ways of modelling the effects of IeS 
on fractures in the Markov structure: ICS may either affect fracture incidence indirectly, through 
effects on bone mineral density (BMD), or through a direct effect on the risk of fracture. While 
these represent the same clinical process, the mathematical process of describing ICS effects differs 
between the two methods. 
5.4.1 Method 1: ICS Affect Bone Mineral Density 
The most commonly used clinical estimate of an individual's BMD status is the T -score, computed 
as T = x-R where x is a patient's BMD measurement (typically in g/cm2), R is the population 
SR 
reference BMD value for someone of the patient's age, sex, and ethnicity, and SR is the standard 
deviation of the reference value. Individuals with a T-score between -1 and -2.5 arc considered to 
have osteopenia, a slight reduction in BMD, while those with a T-score less than -2.5 are categorized 
as osteoporotic, and arc at significantly increased risk for fractures. It has been demonstrated that 
individuals with lower B1rlD arc at a higher risk for fractures; BMD is the strongest predictor of 
fracture risk, and the relative risk of fracture per unit decrease in T-score appears to be approx-
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imately 2.5 [6J. Under the assumption that leS affect fractures because of the typical steroidal 
effects on BMD, several variables must be considered: 
• The relationship between BMD and fracture risk, 
• The relationship between leS and BMD, 
• Baseline BMD, preferably in a eOPD population, and 
• Rates of change of BMD in eOPD patients, both ICS users and non-users. 
Once these variables are described appropriately, the effects of lCS on fracture risk, modelled 
through bone density changes, will be simple to estimate. 
The Dubbo study observed BMD loss over time in their participants [21]. They found that 
the average rate of BMD loss in women was 0.96% per year (0.64% to 1.28%), and 0.82% per year 
among men (0.5% to 1.12%). Regression modelling showed that the strongest predictors of BMD 
loss were age, baseline BMD, and BMI, and that significant interactions were present between age 
and dietary calcium in women, and quadriceps strength and dietary calcium in men. Similar results 
were obtained in a review by Levis and Altman [63J, who concluded that the typical rate of BMD 
loss is up to 1 % yearly in normal adults, but rises to 2--4% yearly among menopausal women. 
Iqbal's [18] study of BMD in men with lung disease shed much light on the relationship between 
lung disease, corticosteroid therapies, and BMD. They found that their participants with chronic 
lung disease (COPD or asthma) had notably lower BMD than men without lung disease, regardless 
of corticosteroid usage, suggesting that the disease process itself contributes strongly to the loss 
of bone density. The fact that smoking contributes to both COPD development and BMD loss 
may support this hypothesis. Among those who used corticosteroids, oral users and inhaled users 
did not differ in their proportions diagnosed with osteopenia or osteoporosis. Iqbal concluded that 
individuals with chronic lung disease who had never used corticosteroids were 5 (0.78-30.7) times 
as likely as controls to have osteoporosis, while those who had been treated with corticosteroids 
were approximately 9 times as likely (1.8-44). 
A study of the causes of bone loss among untreated eOPD patients [25] found that BMD is 
significantly lower in COPD patients than non-COPD controls (T-score -1.628 vs. -0.058, respec-
tively). Measurements of total BMD, trabecular BMD, and cortical BMD indicated that eOPD 
patients have 67-80% of the BMD of non-COPD controls. As the eOPD patients in this study were 
"untreated," the decreased BMD among eOPD patients is unlikely to have been caused by the use 
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of systemic or inhaled corticosteroids. However, the smoking exposure of COPD participants was 
significantly higher than that of controls (32.6 vs. 9.8 pack-years); this may be one contributor to 
the differences observed. 
The Lung Health Study Research Group [24] trial of inhaled triarncinolone (leS) in COPD 
observed a difference in percentage BMD decline between lCS users and nonusers of 1.78 (in favor 
of placebo) when measured at the femoral neck (hip). However, the EUROSCOP trial of inhaled 
budesonide [52] observed no differences in BMD loss between lCS users and nonusers, and a meta-
analysis of the effects of lCS on BMD [48] found no effect, either overall or when restricted to 
COPD. Because of the differing results of these trials, it has been hypothesized that the effect of 
les on BMD may depend on the type of lCS studied. 
Given the average rate of BMD loss, the typical baseline BMD measurement for an individual 
of a certain age and sex, baseline fracture incidence rates, and the relationship between fracture 
risk and BJVID, it is possible to construct a function to estimate the risk of fracture at any point 
in time. The model assumes that individuals enter the sinlulation with the average bone density 
for their age and disease status. The rate of bone density loss is applied to this baseline density 
to compute the expected density and T-score for each model iteration. As described earlier, the 
baseline risk of fracture then increases for each decrease of one unit in the T-score from baseline. 
Linear regression of T -scores on time (years) estimates the average yearly decline in T -score for 
use in the risk estimating function (Tables 5.7 and 5.8). Because the fracture incidence estimates 
begin at age 60, it is unnecessary to take menopausal BMD loss into account. The average decline 
in density is computed, for no lCS effects, by applying the bone density reduction observed in the 
Dubbo study to baseline BMD estimates. The additional impact of hypothesized lCS effects were 
incorporated through applying the bone density loss observed in the Lung Health Study. 
Table 5.7: Estimated average yearly decline in T-score (non-COPD) 
Sex 60-69 70-79 80+ 
Male 0.04596 0.04398 0.03852 







We apply the risk ratio for fractures to the population estimates of incidence to yield transition 
probabilities as follows: 
rate 8 
P(fracture) = 1 - exp(--.~ * RR *t), 
tzme 
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Table 5.8: Estimated average yearly decline in T-score (COPD [25]) 













Table 5.9: Hip fracture incidence by age group, Dubbo, Australia [38] 
60-65 65--70 70-75 75--80 80--85 85+ 
Male 0 80 200 280 1050 1187 
Female 116 250 200 625 1700 2597 
Incidence per 100,000 person-years 
where b denotes the average yearly decline in T -score and t represents the iteration (yearly). This 
model assumes an exponential model and proportional hazards between treatment groups. 
5.4.2 Method 2: rcs Increases Fracture Risk 
A different way to model the effects of rcs on fractures is to disregard the known relationship 
between corticosteroids and BMD, and simply multiply typical fracture incidence rates according 
to the estimated relative risk of fracture among rCS-using COPD patients relative to non-users. 
The Dubbo osteoporosis study described the incidence of hip fractures according to age and gen-
der [38]; these are described in Table 5.9. 
A retrospective cohort based on the UK's General Practice Research Database [79] examined 
the incidence of osteoporotic fractures among three population groups: inhaled corticosteroid users, 
bronchodilator users, and control patients. The analysis found that rcs users were 20% more likely 
to develop a hip fracture than bronchodilator users (0.99-1.45), and 22% more likely than controls 
(1.04--1-43). rn a dose-dependent analysis, the authors found that only users of high doses had a 
statistically significant increased risk of fracture: high-dose ICS users were 59% (1.24-2.03) and 
77% (1.31-2.40) more likely to experience a hip fracture than bronchodilator users and controls, 
respectively. However, because patients with respiratory disease commonly smoke and obtain in-
sufficient exercise, both of which are risk factors for osteoporosis, the authors concluded that the 
results were due, at least in part, to the underlying illness being treated with lCS. As part of a 
different study drawn on GPRD data, Hubbard's [61] examination of the relationship between hip 
fractures and exposure to inhaled and oral steroids found a strong trend in odds ratios, according 
to the dose of res, after adjustment for oral corticosteroid prescriptions. When the analysis was 
repeated after excluding individuals who had ever been prescribed oral corticosteroids, the trend 
was less significant (p = 0.013), and several of the odds ratios lost statistical significance. The 
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overall odds ratio associated with IGS exposure was 1.26 (1.17~ 1.36). After controlling for oral 
steroid use, the odds ratio decreased slightly to 1.19 (1.10~ 1.28). 
Lee and Weiss' [74] analysis of nonvertebral fractures in a Veterans' Affairs (VA) GOPD cohort 
found that individuals with a fracture were 1.29 times as likely to be current IGS users than individ-
uals without a fracture (unadjusted odds ratio 1.02~ 1.64, adjusted odds ratio 0.94~ 1.54). When the 
analysis was restricted to participants that contributed 2+ years of followup data, patients with a 
fracture were significantly more likely to be classified as a current (within 30 days) or recent (within 
90 days) user: the odds ratio for current use was 1.48 (1.03--2.14), and the odds ratio for recent use 
was 1.5 (1.15---1.96). When a dose-dependent analysis was performed, those with a fracture were 
2.45 (1.42--4.22) times as likely to be high-dose IGS users as those without a fracture. Additional 
analysis found that the occurrence of a fracture was not related to the "recency or cumulative 
dose of oral corticosteroid exposure". In an analysis restricted to participants unexposed to oral, 
corticosteroids, there was no notable change in the odds ratio. 
Suissa's [68] study of inhaled and nasal corticosteroids' effects on osteoporotic fractures failed 
to observe an increased risk of hip fractures for current IGS users (relative risk 0.97, 0.92-1.03). 
However, the study did identify a significantly increased risk of upper extremity fractures. The risk 
of hip fracture was significantly increased only among individuals who used a daily dose greater 
than 2,000 /--Lg (beclomethasone-equivalent units), but this high dose is not commonly prescribed. 
Lau's [15] study of the relationship between IGS prescription and hospitalization for hip fracture 
found no difference in risk of hospitalization between leS users and proton pump users (controls). 
An significantly increased risk was observed among systemic corticosteroid users. 
For the purposes of modelling, the relative risk describing the effect of IGS must either be 
chosen or synthesized from the literature described above. Among the studies that found an effect, 
the minimal increase in risk appears to be around 20%, with an upper limit of approximately 50%. 
Hubbard's overall OR of 1.26 (1.17~ 1.36) seems to be representative of the estimates. Applying this 
approximation of the relative risk to the baseline fracture rates observed in the Dubbo osteoporosis 
study (Table 5.9) results in estimates of fracture rates for IGS non-users and users (Table 5.10), 
and the transition probabilities computed from those fracture rates are contained in Table 5.11. 
5.5 Transitions from Recovering Fracture to Fractured 
In a summary and meta-analysis of the relevant literature, Klotzbuecher [8] described the risk 
of second fractures among individuals who have experienced a first osteoporotic fracture of the 
wrist, vertebrae, or hip. She found that peri/post-menopausal women who had experienced a 
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Table 5.10: Estimated fracture rates, per 100,000 person-years 
Male Female 
Age rcs non-user rcs rcs non-user ICS 
60-64 0 0 116 146 
65-69 80 101 250 315 
70-74 200 252 200 252 
75-79 280 353 625 788 
80-84 1,050 1,320 1,700 2,140 
85+ 1,187 1,500 2,597 3,270 
Table 5.11: Transition probabilities for the move between never fractured and fractured 
Age Male Male, ICS Female Female, rcs 
60-64 0 0 0.00112 0.00146 
65-69 7.76x10-4 0.00101 0.00242 0.00315 
70-74 0.00194 0.00252 0.00194 0.00252 











hip fracture were 2.3 (1.5-3.7) times as likely as unfractured individuals to experience a second 
fracture. Generally, individuals with a hip fracture were 1.6 (1.3-1.9) times as likely to develop 
another hip fracture. Table 5.12 describes the estimated fracture incidence rates for individuals 
who have already experienced a fracture, derived by applying these relative risks to the estimated 
fracture incidence rates shown in Table 5.10. Based on those rates, the transition probabilities for 
the move from recovering fracture to fractured were computed in the traditional manner, and are 
contained in Table 5.13. 
Table 5.12: Estimated fracture rates among already-fractured individuals 
Male Female 
Age r cs non-user rcs ICS non-user rcs 
60-64 0 0 270 340 
65-69 130 160 580 720 
70-74 320 400 460 580 
75-79 450 560 1,400 1,800 
80-84 1680 2,100 3,900 4,900 
85+ 1,900 2,400 6,000 7,500 
Incidence per 100,000 person-years 
5.6 Cost Weights 
The COPD-related cost weights for this model were estimated from the study by Hilleman [12]. 
The results of this study of COPD costs are summarized in Table 5.14. In this study, the annual 
median treatment cost for COPD per patient began at around $1700 among individuals with Stage 
I COPD, and increased to a median of $10,800 among those with Stage IV COPD. 
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Table 5.13: Transition probabilities for the move from recovering fracture to fractured 
Age Male Male, ICS Female Female, ICS 
60-64 0 0 0.00266 0.00336 

















Table 5.14: Annual median per-patient cost [12] 
Stage I Stage II/III Stage IV 
Pu blished costs $1,681 $5,037 $10,812 
ICS-adjusted costs $1,681 $4,961 $10,611 
Inflated (2004) Costs $2,471 $7,291 $15,595 
The original published costs could have been used as baseline costs for different stages of 
COPD, except that the costs include the cost of ICS therapy. While this is negligible among Stage-
I patients (less than 3% of the Stage I patients studied used ICS), the utilization rate was higher 
among Stage II/III and IV patients studied (11 % and 29% higher than Stage I, respectively). Thus, 
the total yearly costs for Stages II/III and IV were adjusted for ICS costs by subtracting 11 % and 
29% of the yearly IeS cost ($85/month, $1020/year in 2004 [1], CPI adjusted to $694 yearly). 
A Mayo Clinic study [71] of the direct costs following osteoporotic hip fractures found that 
individuals with a hip fracture incurred a median increase in direct medical costs of $10,338 during 
the year following their fracture date (1995 dollars). Another study at the University of Georgia [5] 
observed a $8,986 increase per year in Medicaid expenditures for hip fracture patients. Similarly, 
a study of the economic impact of osteoporosis in California [81] found that the mean cost of a hip 
fracture was $8,358 at the time of hospital discharge. Based on these estimates, we chose a fairly 
high cost of $10,000 (1995 dollars) to be incurred by each fracture. As above, this cost was inflated 
to 2004 dollars according to the 1995 and 2004 medical costs CPI (1995 CPI 220.5, inflated price 
$14,063) and then discounted at the rate of 3% per year. 
The final matrix of starting costs for each model state, according to CO PD stage, can be found 
in Table 5.15. 
5.7 Health-Related Quality of Life Weights 
Osteoporotic fractures of the hip are extremely painful, requiring hospitalization and, often, long-
term care, and thus generally effect a significant decrease in patient HRQoL. As part of a systematic 
review and cost-utility analysis, Kanis [30] provided a tabulation of health state utility values for 
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Table 5.15: Cost weights at model initiation 
Unfractured Fractured Recovering Fracture 
Stage I, no ICS $2,471 $16,534 $2,471 
Stage II/III, no IeS $7,291 $21,354 $7,291 
Stage II/III, ICS $8,311 $22,374 $8,311 
Stage IV, no ICS $15,595 $29,658 $15,595 
Stage IV, ICS $16,615 $30,678 $16,615 
various osteoporotic states. Based on a massive review of the pertinent clinical literature, Kanis 
suggested 0.797 as the "multiplier for the proportionate effect of a fracture on HSVs (health state 
values) in the first year" (parenthetical comment mine). The review concluded that the effect 
after one year might be approximately one-half the effect during the first year (0.90). Thus, these 
estimates will be combined with the HRQoL weights computed for Stage II/III and IV COPD 
(described in Section 4.7). A HRQoL weighting function that summarizes the information above 
may be constructed as follows: 
QT = 1.03-T [Qo - (0.032 - M)T] 0.797F O.9R , where 
• QT represents the QoL weight for a given state at time T 
• Qo is the initial HRQoL weight; this varies by COPD stage as described above 
• M represents the difference in HRQoL decrease between ICS users and ICS non-users, and 
may be assigned values to reflect no difference (M = 0), a small difference (M = 0.012), or a 
large difference (M = 0.025) 
• F= 1 for fractured state, F=O otherwise 
• R=l for recovering fracture state, R=O otherwise 
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Chapter 6 
Results: Model of Disease Progression 
This Markov model drew information from a large variety of clinical trials and observational studies 
with the goal of assessing the effects of lCS on COPD progression and exacerbations through a 
traditional st9chastic modelling approach. Several parameters were allowed to vary in this model, 
including gender, age, level of mortality from COPD exacerbations, and the effects of leS on eOPD 
Inortality and patient HRQoL. 
6.1 Cost-utility Analysis 
Table 6.1 describes the cost-utility of leS among a cohort of 100 individuals age 50 for a variety of 
model parameter combinations. Among females, the reference model with no leS usage resulted 
in the following results: (A) 54.31 QALYs, $1,046,500, (B) 50.84 QALYs, $958,620, and (e) 47.76 
QALYs, $881,780. Within this baseline case, the effects of increasing the mortality of exacerbations 
are well-illustrated (the cases represent 5%, 10%, and 15% mortality, respectively). There is a 
slight decrease in the total QALY s lived by the cohort, and a stronger drop in the total costs is 
also evident (probably due to a reduction in cohort size). In the worst case (case (A) vs. case (C)), 
the decrease in QALYs lived is approximately 24 days per person. This trend of decreasing QALYs 
and costs is also present for males, among whom the model yielded estimates of (A) 64.27 QALYs, 
$736,490, (B) 60.26 QALYs, $684,140, and (C) 56.66 QALYs, $637,620. The difference in total 
QALY s lived among males was around 28 days in the most extreme comparison, suggesting that 
increases in exacerbation mortality may disproportionately affect males to a slight degree. However, 
it should be noted that in all models, males lived a greater number of QALY s: the differential was 
approximately one additional quality-adjusted month per person among males, with slight variation 
according to model conditions. 
It is apparent that in all cases, lCS use results in cost savings. lCS use did not decrease the 
number of QALYs lived in any modeL In all cases, IeS use also decreases total costs. The cost 
savings range from a minimum of $8,020 per QALY gained to a maximum of $171,656 per QALY 























Table 6.1: Cost-utility of lCS among 50 year old COPD sufferers 
No reduction in mortality 15% reduction in mortality 30% reduction in mortality 
Effect on HRQoL Effect on HRQoL Effect on HRQoL 
None Small Large None Small Large None Small Large 
Cost ($) 821,630 821,630 821,630 827,820 827,820 827,820 834,080 834,080 834,080 
QALYs 55.62 56.84 58.16 55.94 57.18 58.52 56.27 57.52 58.87 
$/QALY -171,656 -88,881 -58,408 -134,160 -76,195 -51,943 -108,378 -66,174 -46,583 
Cost ($) 782 laO , 782,130 782,130 793,670 793,670 793,670 805,470 805,470 805,470 
QALYs 53.55 54.68 55.90 54.15 55.31 56.56 54.77 55.96 57.24 
$/QALY -65,125 -45,961 -34,879 -49,834 -36,902 -28,837 -38,969 -29,912 -23,930 i 
Cost ($) 745,520 745,520 745,520 761,650 761,650 761,650 778,340 778,340 778,340 
QALYs 51.61 52.66 53.88 52.47 53.55 54.73 53.35 54.57 55.69 
$/QALY -35,392 -27,808 -22,265 -25,505 -20,748 -17,235 -18,504 -15,189 -13,044 
Cost ($) 584,290 584,290 584,290 587,910 587,910 587,910 591,570 591,570 591,570 
QALYs 66.74 67.96 69.29 67.11 68.35 69.69 67.48 68.73 70.09 
$/QALY -61,619 -41,247 -30,319 -52,317 -36,417 -27,413 -45,146 -32,493 -24,900 
Cost ($) 561,030 561,030 561,030 567,840 567,840 567,840 574,800 574,800 574,800 
QALYs 64.35 65.49 66.74 65.05 66.22 67.49 65.76 66.96 68.25 
$/QALY -30,100 -23,539 -18,998 -24,280 -19,513 -16,086 -19,880 -16,319 -13,685 ' 
Cost ($) 539,230 539,230 539,230 548,860 548,860 548,860 558,780 558,780 558,780 
QALYs 62.01 63.17 64.34 63.09 64.20 65.40 64.12 65.26 66.49 
$/QALY -18,391 -15,114 -12,811 -13,804 -11,772 -10,156 -10,568 -9,167 -8,020 
(A) 5% exacerbation mortality, (B) 10% exacerbation mortality, (C) 15% exacerbation mortality 
savings decrease with increasing exacerbation mortality, increasing mortality benefit from IeS, and 
strengthening HRQoL effects. 
The effects of exacerbation mortality (cases (A), (B), and (e)) are consistent throughout the 
model. Table 6.2 demonstrates the effect of cohort age on the cost-utility of IeS in a simulation of 
60 and 70 year old females and males with COPD in the central case of 10% exacerbation mortality. 
The baseline model of no IeS use resulted in 53.98 QALYs lived and costs of $854,260 among 60 
year old females, 55.42 QALYs lived and costs of $779,900 among 70 year old females, 55.46 QALYs 
lived and costs of $798,510 among 60 year old males, and 52.92 QALYs lived and costs of $822,840 
among 70 year old males. The cost-utility ratio consistently decreases in magnitude with age among 
females, but increases in magnitude with age among males. 
6.2 Distribution of Time in Model States 
Table 6.3 describes the distribution of time spent in the model states, as well as the percent of 
mild to total exacerbations (Severity Ratio), and the ratio of time spent in Stage II/III to the total 
non-exacerbated time (Stage Ratio). These results indicate that ICS use increases the fraction of 
tilne spent in a stable (non-exacerbated) state of COPD, and approximately doubles the fraction of 
mild exacerbations. ICS use does not appear to slow the rate of progression into more severe stages 
of COPD; however, because the fraction of time spent in Stage IV increases (albeit slightly) as the 
mortality benefit of ICS strengthens, the increased time spent in Stage IV may be attributable to 
the lower mortality rate of the rCS-using cohort. Strengthening the mortality benefit attributable 
to ICS use does not result in any appreciable change in the distribution of time, nor in the severity 
or stage ratios. When the effects of age are examined under model condition (B) (Table 6.4), 
it appears that the trends observed among 50 year-old individuals continue for the older cohorts. 
N either the distribution of time across model states nor the severity ratio vary by age. However, the 
stage ratio increases with age among females (more time spent in Stage II/III COPD), but decreases 
among males. This interesting finding may be an artifact of the NHANES data used to estimate 
the probabilities of transition between Stages II/III and IV, and will bear further examination. 
6.3 Discussion 
Inhaled corticosteroids are a COPD therapy with a mixed history. To date, clinical measurement of 
FEV 1 has been the primary marker of COPD stage, but ICS have (arguably) failed to demonstrate 
a significant effect on that quantity. IeS are known to reduce the number of exacerbations, and may 
reduce their severity. The Markov model presented above summarizes this published information, 
















Table 6.2: Cost-utility of ICS among 60 and 70 year old COPD sufferers, under model condition (B) 
No reduction in mortality 15% reduction in mortality 30% reduction in mortality 
Effect on HRQoL Effect on HRQoL Effect on HRQoL 
None Small Large None Small Large None Small Large 
Cost ($) 696,370 696,370 696,370 706,210 706,210 706,210 716,290 716,290 716,290 
60 QALYs 57.22 58.35 59.70 57.85 59.00 60.24 58.49 59.66 60.93 
$/QALY -48,731 -36,130 -27,603 -38,256 -29,492 -23,650 -32,387 -24,290 -19,852 
Cost ($) 620,380 620,380 620,380 628,590 628,590 628,590 636,970 636,970 636,970 
70 QALYs 59.68 60.79 61.98 60.32 61.45 62.67 60.97 62.13 63.37 
$/QALY -27,986 -23,424 -19,940 -23,866 -20,256 -17,412 -20,448 -17,537 -15,222 
Cost ($) 650,640 650,640 650,640 659,520 659,520 659,520 668,580 668,580 668,580 
60 QALYs 58.97 60.08 61.30 59.60 60.75 61.98 60.25 61.42 62.68 
$/QALY -42,128 -32,006 -25,320 -33,572 -26,274 -21,317 -27,125 -21,800 -17,996 
Cost ($) 673,620 673,620 673,620 682,970 682,970 682,970 692,520 692,520 692,520 
70 QALYs 55.89 56.96 58.13 56.49 57.58 58.77 57.10 58.22 59.43 
$/QALY -50,242 -36,936 -28,641 -39,179 -30,015 -23,909 -31,177 -24,589 -20,018 






Table 6.3: Distribution of time across model states for individuals age 50 
Females Males 
% Mild % Major Sev. Stage % Mild % Major Sev. 
% Stable Exac. Exac. Ratio Ratio % Stable Exac. Exac. Ratio 
NolCS 90.59 2.08 7.33 22.15 26.9 91.84 1.81 6.36 22.12 
lCS, RR== 1.0 93.07 2.85 4.08 41.07 23.81 94.11 2.42 3.48 40.97 
lCS, RR== 0.85 93.07 2.85 4.09 41.07 23.65 94.11 2.42 3.48 40.97 
leS, RR== 0.70 93.07 2.85 4.09 41.07 23.48 94.11 2.42 3.48 40.97 
.. 
NolCS 90.61 2.08 7.3 22.16 28.98 91.85 1.8 6.35 22.13 
leS, RR== 1.0 93.08 2.84 4.08 41.07 24.91 94.11 2.42 3.48 40.98 
leS, RR== 0.85 93.08 2.84 4.08 41.07 24.58 94.11 2.41 3.48 40.97 
leS, RR= 0.70 93.07 2.84 4.08 41.07 24.25 94.11 2.42 3.48 40.97 
.- . 
Noles 90.65 2.07 7.28 22.17 31.1 91.85 1.8 6.34 22.14 
leS, RR== 1.0 93.09 2.84 4.07 41.07 26.03 94.11 2.41 3.48 40.98 
leS, RR== 0.85 93.09 2.84 4.08 41.07 25.52 94.11 2.41 3.48 40.98 
leS, RR== 0.70 93.08 2.84 4.08 41.07 25.02 94.11 2.42 3.48 40.98 
(A) 5% exacerbation mortality, (B) 10% exacerbation mortality, (e) 15% exacerbation mortality 
Sev. Ratio: % exacerbated time spent in mild exacerbations; Stage Ratio: % stable time spent in stage II/III eOPD 



















Table 6.4: Distribution of time across model states for individuals age 60 and 70, model condition (B) 
Females Males 
% Mild % Major Sev. Stage % Mild % Major Sev. 
% Stable Exac. Exac. Ratio Ratio % Stable Exac. Exac. Ratio 
NolCS 91.00 1.99 7.00 22.15 46.11 91.23 1.94 6.83 22.15 
ICS, RR== 1.0 93.40 2.71 3.89 41.04 43.59 93.60 2.63 3.78 41.02 
leS, RR== 0.85 93.40 2.71 3.89 41.04 43.24 93.59 2.63 3.78 41.02 
ICS, RR== 0.70 93.39 2.71 3.90 41.04 42.88 93.59 2.63 3.78 41.02 
NolCS 91.29 1.93 6.78 22.10 58.83 91.04 1.99 6.98 22.15 
ICS, RR== 1.0 93.72 2.58 3.70 41.01 62.34 93.41 2.70 3.88 41.04 
ICS, RR== 0.85 93.72 2.58 3.71 41.01 62.05 93.41 2.70 3.89 41.04 
leS, RR== 0.70 93.71 2.58 3.71 41.01 61.76 93.41 2.71 3.89 41.04 
Sev. Ratio: % exacerbated time spent in mild exacerbations; Stage Ratio: % stable time spent in stage II/III COPD 











to increasingly severe stages of COPD, and exacerbation frequency and severity. These estimates 
show that, under the assumptions of this model, ICS use results in cost savings and increased 
QALYs lived. However, these results differ dramatically from those of two other cost-effectiveness 
studies recently published on this topic. 
The recently published model by Spencer and co-workers [45J assessed the cost-effectiveness of a 
combination ICS with fJ2-agonist compared to standard care. Their model was based on the results 
of a single one-year clinical trial (TRISTAN), and found a cost-utility ratio of $11,125 to $74,887 per 
QALY. Like the model by Sin, Golmohammadi, and Jacobs [10], their model included three stages 
of COPD, an exacerbation state, and death, the model iteration period was three months, and the 
model used Monte Carlo methods to reflect uncertainty in the estimated parameters. However, the 
two existing models differ from the one presented herein in several ways: 
• Spencer's model completed separate simulations for smokers and ex-smokers. The model 
presented here used a reversible jump between smoking and ex-smoking submodels, extending 
its clinical validity and creating the possibility of future application to assess the effects of 
smoking cessation therapies on COPD progression and exacerbations. 
• It is unclear whether Spencer's model permits ICS use to affect COPD mortality alone. The 
model by Sin et. al. assumed that ICS use impacted all-cause mortality. As the use of IeS 
in the COPD population has not been shown to reduce death from non-COPD causes, our 
model restricts the mortality effects of ICS to COPD death alone. 
• The exacerbation rates and proportions of mild and moderate/severe exacerbations estimated 
from the TRISTAN clinical trial were different from those found in the literature and used 
in this model; specifically, the exacerbation rates were on the lower range of the literature 
summarized in Table 4.5, and the proportion of major exacerbations was much lower in the 
TRISTAN trial than in other studies. It also appears that neither Spencer's nor Sin's models 
permit ICS to affect the distribution of exacerbation severity, unlike the model presented here. 
As severe exacerbations account for the majority of COPD costs, this is a critical factor to 
consider during a cost effectiveness analysis. 
• The analyses by Spencer and Sin did not account for decreases in patient HRQoL over time, 
such as those observed in the ISOLDE trial [56]. Also, Spencer's model assumed an equal 
patient HRQoL during hospitalization, regardless of the stable severity state, while Sin's 
model assumed an equal decrement in HRQoL for mild and severe exacerbations. The model 
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presented here allowed the HRQoL weights for exacerbation states to vary according to the 
stable state of origin and also according to the level of exacerbation. 
Without additional details regarding Spencer's model, a direct comparison cannot be performed. 
The publication fails to describe explicitly the effects of ICS on the parameters that ICS may affect, 
citing "current evidence and data that may become available in the future." It is not clear that 
the differing results of the three models implies lack of validity of any. Rather, the questions raised 
regarding the effects of differences in the models' assumptions and structures make clear the need 
for further investigation in this area. 
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Chapter 7 
Results: Model of Osteoporotic Fractures 
This Markov chain summarizes the clinical literature pertaining to the effects of ICS on bone density 
and osteoporotic fractures to assess the cost-utility of these medications when side effects concern-
ing bone health are taken into account. The model was constructed to permit this assessment 
under a range of assumptions relating to ICS effects on mortality and HRQoL. Because the model 
results do not differ notably by gender, the results for males have been placed in the Appendix 
for reference. The attentive reader will recall that two methods were used for the derivation of 
transition probabilities to the fractured model state. The results for these methods were extremely 
similar; hence, the output for Method 2 has also been placed in the Appendix. 
7.1 Stage II/III COPD 
Under the assumptions that ICS do not directly decrease patient mortality (Table 7.1) and that 
they slow the decline in patient HRQoL, les are found to be of value according to the traditional 
threshold of $50,000/QALY. When there is no effect on HRQoL, the number of QALYs lived is 
equal between ICS users and nonusers, indicating that the additional osteoporotic fractures incurred 
by ICS use do not significantly decrease the number of QALYs lived, i.e. the penalty to HRQoL 
associated with leS-induced fracture occurrence is minimal. If there is a small effect on HRQoL, 
the cost per QALY is approximately $15,000, while if the effect on HRQoL is large, the resultant 
increase in QALYs lived forces the cost per QALY down to around $7,000. 
Table 7.1: Cost-utility of ICS among females with Stage II/III COPD when ICS does not change 
mortality 
Effect on HRQoL 
None Small Large 
NolCS 
Cost ($) 7,202,900 7,202,900 7,202,900 
QALYs 402.96 402.96 402.96 
les 
Cost ($) 8,208,400 8,208,400 8,208,400 
QALYs 402.96 470.70 281.85 
$/QALY - 14,844 7,124 
When the model considers the possibility that ICS reduce patient mortality (Table 7.2), the 
cost-utility ratio for les decreases relative to the instance of no mortality benefit. Under the 
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Table 7.2: Cost-utility of ICS among females with Stage II/III COPD when IeS changes mortality 
15% reduction in mortality 30% reduction in mortality 
Effect on HRQoL Effect on HRQoL 
None Small Large None Small Large 
ICS 
Cost ($) 8,699,600 8,699,600 8,699,600 9,246,400 9,246,400 9,246,400 
QALYs 421.65 496.94 578.5 441.99 525.84 616.68 
$/QALY 80,080 15,926 8,526 52,357 16,630 9,562 
condition of a 15% reduction in mortality, the cost-utility ratio remains above threshold when 
there is also no effect on HRQoL; however, this ratio drops rapidly in the presence of either a small 
or large effect on HRQoL. If the reduction in patient mortality increases to 30%, the cost-utility 
ratio of ICS again remains marginally above threshold for the model with no HRQoL effects, but 
drops well below the $50K threshold when there are small or large HRQoL effects. 
7.2 Stage IV COPD 
When the model assumes that ICS do not alter Stage IV patient mortality (Table 7.3), their use 
produces a cost-utility ratio below the traditional threshold for either small or large HRQoL effects. 
When either the 15% or 30% level of mortality benefit is assumed (Table 7.4), both the small and 
large HRQoL effects yield cost-utility ratios below threshold. 
Table 7.3: Cost-utility of ICS among females with Stage IV COPD when ICS does not change 
mortality 
Effect on HRQoL 
None Small Large 
NolCS 
Cost ($) 12,980,000 12,980,000 12,980,000 
QALYs 209 209 209 
IeS 
Cost ($) 13,829,000 13,829,000 13,829,000 
QALYs 209 254.48 307.56 
$/QALY - 18,668 8,614 
Table 7.4: Cost-utility of les among females with Stage IV COPD when ICS changes mortality 
15% reduction in mortality 30% reduction in mortality 
Effect on HRQoL Effect on HRQoL 
None Small Large None Small Large 
ICS 
Cost ($) 14,904,000 14,904,000 14,904,000 16,151,000 16,151,000 16,151,000 
QALYs 218.99 271.21 332.69 229.9 290.11 361.67 
$/QALY 192,593 30,928 15,555 151,722 30,095 20,770 
7.3 Distribution of Time 
Another interesting result of the model is the distribution of time spent by the simulated 100-person 
cohort in the different model states over 20 years. This distribution is described in Table 7.5. For 




Table 7.5: Distribution of time across model states and percentage of time spent in each state 
Women Men 
Mortality COPD Never Recov. Never Recov. 
Effect Stage Fractured Fractured Fracture Total Fractured Fractured Fracture 
II/III 1112.2 3.18 19.22 1134.6 1127.3 0.97 6.3 
% 98.03 0.28 1.69 99.36 0.09 0.6 
No effect II/III, ICS 1111.2 3.47 19.92 1134.59 1127 1.05 6.7 
% 97.94 0.31 1.76 99.33 0.09 0.58 
15% II/III, ICS 1197.6 3.78 22.31 1223.69 1215 1.14 7.36 
% 97.87 0.31 1.82 99.31 0.09 0.6 
30% II/III, ICS 1294.9 4.12 2.04 1324.06 1314.5 1.24 8.27 
% 97.8 0.31 1.89 99.28 0.09 0.6 
IV 892.24 2.5 13.59 908.33 902.91 0.82 4.62 
% 98.23 0.28 1.5 99.4 0.09 0.51 
No effect IV,ICS 891.59 2.7 14.05 908.34 903.13 0.77 4.44 
% 98.16 0.2 1.55 99.43 0.08 0.49 
15% IV,ICS 983.38 3.02 16.47 1002.87 996.53 0.92 5.42 
% 98.06 0.3 1.64 99.37 0.09 0.54 
30% IV,ICS 1091.6 3.4 19.38 1114.38 1107 1.03 6.39 
% 98.95 0.31 1.74 99.33 0.09 0.57 












live a total of 1134.6 years. Of this time, 98.03% will be spent having never experienced a fracture. 
As a group, 0.28% of their time will be spent in the fractured state, and 1.69% of their time will 
be spent in the recovering fracture state. This group lived for an average of 11.35 years. 
The implications of the postulated effects of ICS are made clear in this table. When no direct 
mortality effect is assumed, the total years lived remains approximately the same, although a small 
amount of unfractured time is redistributed between the fractured and recovering fracture model 
states. For women, this redistribution of time is equivalent to 7.9 hours per person-year being 
removed from the unfractured state. When the mortality effect is 15%, approximately 14 hours are 
redistributed, and when the mortality effect is 30%, approximately 20 hours are redistributed. In 
the COPD Stage II/III cohort, ICS use fails to increase mortality; specifically, there are no cases 
in which the increase in mortality pursuant to fracture exceeds the mortality benefit hypothesized 
for ICS. 
When the amount of time spent in the fractured model state is examined, we find that, on 
average, women with stage II/III COPD experience an increase of 2.6 hours per year when the 
most extreme cases are compared (no ICS vs. ICS with 30% benefit to mortality); this increase is 
the same among women with stage IV CO PD. The increase experienced be men is small enough as 
to not be detectable after numerical rounding. Overall, these are miniscule effects. 
Finally, it is apparent in the model output, as in reality, that women are at an increased risk of 
fracture relative to men. In this model, women spend up to 3.4 times as much time in the fractured 
state as men. 
7.4 Discussion 
The effects of inhaled corticosteroids on bone density, and the potential effects on osteoporotic 
fracture incidence, have long been a topic of discussion within the pulmonary community. The 
concern is not relegated to patients with COPD; children and adults with asthma, who frequently 
use ICS on a regular basis, would also incur the bone health effects of ICS use. Because the history 
of les use in asthma is more prolonged than in COPD, the majority of studies of bone health effects 
have been performed in the asthmatic population. However, the COPD patient population differs 
significantly from the asthmatic population in two critical areas: COPD sufferers are generally in 
their 40s or older at the time of treatment initiation, and individuals with COPD are mostly current 
or ex-smokers, placing them at. a risk of decreased bone mass beyond that incurred by age and lack 
of exercise. Thus, when discussing effects specific to the COPD population, it is important to 
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evaluate the evidence gathered from within that population, although the results of studies in other 
populations should still be borne in mind. 
Several studies have attempted to ascertain the effects of lCS on COPD patient bone health, 
with mixed results. The Lung Health Study [24] observed increased decline in BMD among lCS 
users, while EUROSCOP [52] found no effect attributable to ICS use. Similarly, a meta-analysis [48] 
of the effects among COPD sufferers concluded that there was insufficient evidence to support claims 
of an effect on BMD loss. However, the studies of BMD effects to date may have been statistically 
underpowered to detect a clinically significant change in BMD rates of loss, decreasing the chance 
of detecting an effect if one truly existed. 
By permitting a variety of assumptions regarding the effects of ICS on BMD and fracture in-
cidence, the Markov model has effectively simulated multiple clinical trials in an effort to estimate 
the cohort-level effects of multiple hypothesized BMD results. The model output described above 
demonstrate that, in the worst case, ICS use simultaneously fails to increase patient mortality or 
decrease QAL Y s lived by increasing the incidence of osteoporotic fractures. The increase in time 
spent in the fractured model state is minimal, approximately 2.6 hours per person-year. This is a 
critical and clinically reassuring finding. 
The cost-utility of ICS is suboptimal only when the effect of ICS on patient HRQoL is nonex-
istent or when the effect is small. All other conditions of HRQoL and mortality effects produce 
favorable cost-utility ratios. 
If the relative risk of fracture attributable to ICS increases reasonably, the results with regard 
to mortality and QALY s lived do not change significantly. In fact, assuming no HRQoL benefit and 
a 15% decrease in mortality among males with stage II COPD, a massive relative risk of 100 does 
not even begin to overwhelm the mortality benefit. However, the cost-utility ratio does increase. 
This model has several limitations that should be considered as areas for possible improvement 
in future work: 
• The data used to inform the model were drawn from potentially incomparable populations. 
The fracture incidence rates were estimated from a cohort in Australia, fracture mortality 
data originated in Sweden, and most of the studies of ICS effects were performed in European 
countries, while the cost weights for the model were estimated based on a study performed 
in the United States. The results of the model cannot be interpreted as being specific to a 
single population; neither can they be generalized to a more widely-defined population. 
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• The fracture incidence rates were estimated from a general population, inevitably including 
a number of lCS-using individuals, and do not provide a true "baseline" estimate of fracture 
incidence in the absence of lCS use. Assuming that leS increases fracture incidence, this 
would result in an overestimate of fractures occurring in the model. However, the overestimate 
would occur equally in both les and placebo cohorts . 
• The cost estimates used to estimate cost weights for this model were drawn from a single study. 
Economic analyses may vary according to the methods by which they were performed and 
their source population. Estimates synthesized from multiple studies in similar populations 
would greatly strengthen this aspect of the model. 
While the model suffers from several limitations, none of them are sufficiently severe to render the 
results invalid. This Markov model of the effects of leS on bone density and osteoporotic fractures 
has effectively summarized a large amount of disparate information to provide a clinically useful 




This Markov chain summarizes the clinical literature pertaining to the effects of ICS on bone density 
and osteoporotic fractures to assess the cost-utility of these medications when side effects concerning 
bone health are taken into account. The model was constructed to permit this assessment under a 
range of assumptions relating to ICS effects on mortality and HRQoL. Because the model results do 
not differ notably by gender, the results for males have been placed in this Appendix for reference. 
Two methods were used for the derivation of transition probabilities to the fractured model state. 
The results for these methods were extremely similar; hence, the output for Method 2 was also· 
placed in this Appendix. 
A.l Model of Osteoporotic Fractures, Method 1, Males 
When ICS are assumed to deliver no benefit to patient HRQoL, the cost-utility ratio falls below the 
traditional threshold only when the medications result in a strong reduction in patient mortality. 
Under the assumption that ICS fail to decrease mortality (Table A.l), the cost-utility ratios remain 
reasonable for small and large effects on HRQoL. When ICS reduce mortality by 15% or 30% 
(Table A.2), the cost-utility ratio increases slightly relative to the instance of no mortality benefit, 
but remains above threshold if there is no improvement in HRQoL. 
Table A.l: Cost-utility of ICS among males with Stage II/III COPD when lCS does not change 
mortality 
Effect on HRQoL 
None Small Large 
NolCS 
Cost ($) 7,180,300 7,180,300 7,180,300 
QALYs 403.06 403.06 403.06 
ICS 
Cost ($) 8,184,100 8,184,100 8,184,100 
QALYs 403.06 471.07 544.75 
$/QALY - 14,760 7,084 
The results are similar for the model of stage III COPD, although the cost-utility ratios have 
generally increased. When there is no mortality benefit to ICS users (Table A.3), the cost-utility 
ratio is favorable in the presence of any benefit to patient HRQoL. Under the assumption of either 
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Table A.2: Cost-utility of ICS among males with Stage II/III COPD when ICS changes mortality 
15% reduction in mortality 30% reduction in mortality 
Effect on HRQoL Effect on HRQoL 
None Small Large None Small Large 
ICS 
Cost ($) 8,673,500 8,673,500 8,673,500 9,218,200 9,218,200 9,218,200 
QALYs 421.75 497.33 579.22 442.08 526.27 617047 
$/QALY 79,893 15,840 8,476 52,227 16,450 9,505 
Table A.3: Cost-utility of ICS among males with Stage IV COPD when ICS does not change 
mortality 
Effect on HRQoL 
None Small Large 
NolCS 
Cost ($) 12,962,000 12,962,000 12,962,000 
QALYs 208.97 208.97 208.97 
ICS 
Cost ($) 13,810,000 13,810,000 13,810,000 
QALYs 208.97 254.59 307.88 
$/QALY - 18,588 8,573 
a 15% or 30% reduction in patient mortality (Table Ao4), ICS use has good cost-utility only if some 
HRQoL improvement is also present. 
A.2 Model of Osteoporotic Fractures, Method 2, Stage 11/111 COPD 
Two different methods were used to model the effect of ICS on osteoporotic fractures. The first 
method drew on clinical trial estimates of the effect of ICS use on bone mineral density; the results 
based on this method are presented above and in Chapter 7. The second method, the results of 
which are presented below, disregarded the probable mechanism of action (via bone density) and 
simply multiplied fracture rates by an increased relative risk of fracture. 
U sing this method of fracture rate estimation, there is a small decrease in the number of QAL Y s 
lived by ICS users under the simultaneous assumptions of no HRQoL effects and no mortality 
benefit (Tables A.5 and A.7). This results in an astronomic negative estimate of the cost-utility 
ratio that returns to reasonable levels when a HRQoL benefit is present. When the model assumes 
a 15% reduction in mortality attributable to ICS use, the cost-utility ratio remains above threshold 
if there is no benefit to HRQoL. If a 30% reduction in mortality is implemented, a similar effect is 
Table Ao4: Cost-utility of ICS among males with Stage IV COPD when ICS changes mortality 
15 % reduction in mortality 30% reduction in mortality 
Effect on HRQoL Effect on HRQoL 
None Small Large None Small Large 
ICS 
Cost ($) 14,882,000 14,882,000 14,882,000 16,127,000 16,127,000 16,127,000 
QALYs 218.95 271.32 333.04 229.85 290.23 362.07 
$/QALY 192,385 30,794 15,475 151,580 38,949 20,673 
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Table A.5: Cost-utility of ICS among females with Stage II/III COPD when ICS does not change 
mortality 
Effect on HRQoL 
None Small Large 
NoICS 
Cost ($) 7,223,600 7,223,600 7,223,600 
QALYs 403.01 403.01 403.01 
ICS 
Cost ($) 8,242,900 8,242,900 8,242,900 
QALYs 402.98 470.43 543.51 
$/QALY -34M 15,119 7,255 
Table A.6: Cost-utility of IeS among females with Stage II/III COPD when ICS changes mortality 
15% reduction in mortality 30% reduction in mortality 
Effect on HRQoL Effect on HRQoL 
None Small Large None Small Large 
lCS 
Cost ($) 8,738,900 8,738,900 8,738,900 9,291,300 9,291,300 9,291,300 
QALYs 421.69 496.63 577.82 442.04 525.5 615.92 
$/QALY 81,119 16,186 8,668 52,977 16,881 9,712 
apparent: the cost-utility ratio remails slightly above threshold when there is no HRQoL effect, but 
drops to very reasonable levels in the event of small or large HRQoL effects. These results differed 
very little between the genders. 
A.3 Model of Osteoporotic Fractures, Method 2, Stage IV COPD 
This method of estimating fracture risk resulted in a very small increase of QALY s among ICS 
users when ICS failed to both reduce mortality and increase HRQoL, generating a massive cost-
utility ratio (Tables A.9 and A.ll). The ratio dropped to well below threshold when any HRQoL 
improvement was in place. When the model simulated a 15% or 30% reduction in mortality 
(Tables A.I0 and A.12), but there was no improvement in HRQoL, cost-utility ratios were high. 
The assumption of either a small or large effect on HRQoL brought them below threshold, but they 
remained moderate. These results did not differ notably between the genders. 
Table A.7: Cost-utility of ICS among males with Stage II/III COPD when ICS does not change 
mortality 
Effect on HRQoL 
None Small Large 
NolCS 
Cost ($) 7,199,300 7,199,300 7,199,300 
QALYs 403.07 403.07 403.07 
lCS 
Cost ($) 8,211,000 8,211,000 8,211,000 
QALYs 403.06 470.81 544.21 
$/QALY -101M 14,935 7,168 
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Table A.8: Cost-utility of ICS among males with Stage II/III COPD when ICS changes mortality 
15% reduction in mortality 30% reduction in mortality 
Effect on HRQoL Effect on HRQoL 
None Small Large None Small Large 
lCS 
Cost ($) 8,703,800 8,703,800 8,703,800 9,252,500 9,252,500 9,252,500 
QALYs 421.76 497.04 578.6 442.1 525.94 616.78 
$/QALY 80,498 16,010 8,571 52,606 16,710 9,607 
Table A.9: Cost-utility of rcs among females with Stage rv COPD when rcs does not change 
mortality 
Effect on HRQoL 
None Small Large 
NoICS 
Cost ($) 12,993,000 12,993,000 12,993,000 
QALYs 209.01 209.01 209.01 
rcs Cost ($) 13,852,000 13,852,000 13,852,000 
QALYs 209.02 254.45 307.32 
$/QALY 86M 18,904 8,738 
A.4 Model of Osteoporotic Fractures, Method 2, Distribution of Time 
The distribution of life-years across the model states may be found in Table A.13. Consistent with 
the cost-utility results presented above, this method of estimating fracture risk results in a very 
slight loss of total years lived by the cohort when there is no decrease in mortality attributable 
to ICS use. Accompanying this loss of years lived are increases in the time spent in the fractured 
and recovering fracture model states. This effect is present at both stages of COPD and in both 
genders. These changes are greater than those observed using Method 1, suggesting that the model 
may be sensitive to the method of estimating fracture incidence. 
When a mortality benefit is present, the total years lived increase, and the percent of time 
spent in the never fractured model state decreases according to the strength of the mortality effect. 
As was the case for Method 1, these years lost from never fractured appear to be redistributed 
across the fractured and recovering fracture model states. 
Table A.I0: Cost-utility of ICS among females with Stage IV COPD when ICS changes mortality 
15% reduction in mortality 30% reduction in mortality 
Effect on HRQoL Effect on HRQoL 
None Small Large None Small Large 
ICS 
Cost ($) 14,931,000 14,931,000 14,931,000 16,184,000 16,184,000 16,184,000 
QALYs 219.02 271.17 332.4 229.94 290.08 361.32 
$/QALY 193,606 31,178 15,706 152,461 39,361 20,951 
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Table A.ll: Cost-utility of ICS among males with Stage IV COPD when IeS does not change 
mortality 
Effect on HRQoL 
None Small Large 
NolCS 
Cost ($) 12,975,000 12,975,000 12,975,000 
QALYs 209 209 209 
ICS 
Cost ($) 13,828,000 13,828,000 13,828,000 
QALYs 209.01 254.55 307.64 
$/QALY 85M 18,727 8,648 
Table A.12: Cost-utility of lCS among males with Stage IV COPD when leS changes mortality 
15% reduction in mortality 30% reduction in mortality 
Effect on HRQoL Effect on HRQoL 
None Small Large None Small Large 
ICS 
Cost ($) 14,904,000 14,904,000 14,904,000 16,153,000 16,153,000 16,153,000 
QALYs 218.99 271.28 332.76 229.9 290.18 361.74 




Table A.l3: Distribution of time across model states and percentage of time spent in each state 
Women Men 
I Mortality COPD Never Recov. Never Recov. 
, Effect Stage Fractured Fractured Fracture Total Fractured Fractured Fracture 
II/III 1103.2 6.02 25.39 1134.61 1117 3.33 14.2 
% 97.23 0.53 2.24 98.45 0.29 1.25 
No effect II/III, ICS 1094.2 7.87 32.53 1134.6 1111.9 4.33 18.31 
% 96.44 0.69 2.87 98 0.38 1.61 
15% II/III, IeS 1177.9 8.84 36.94 1223.68 1197.9 4.88 20.89 
% 96.26 0.72 3.02 97.89 0.4 1.71 
30% II/III, IeS 1272 9.97 42.05 1324.02 1294.6 5.52 23.87 
% 96.07 0.75 3.18 97.78 0.4 1.8 
IV 886.99 4.22 17.11 908.32 896.58 2.31 9.41 
% 97.65 0.46 1.88 98.71 0.25 1.04 
No effect IV,leS 880.84 5.52 21.95 908.31 893.13 3 12.145 
% 96.98 0.61 2.42 98.33 0.33 1.34 
15% IV,ICS 970.11 6.47 26.25 1002.83 984.62 3.54 14.647 
% 96.74 0.65 2.62 98.19 0.35 1.46 
30% IV,leS 1075.2 7.65 31.55 1114.4 1092.4 4.21 17.73 
% 96.48 0.69 2.83 98.03 0.38 1.59 
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